# **Author index\***

### A

Abbottsmith CW (see Kereiakes et al). 20% 139:S53-S60 Abramson MA (see Roe et al). 2000;139:945-51 Acker MA (see DeNofrio et al). 2000;139:729-33

Adams KF (see Cuffe et al). 2000;139:15-22 Ades PA, Pashkow FJ, Fletcher G, Pina IL, Zohman LR, Nestor JR. A controlled trial of cardiac rehabilitation in the home setting using electrocardiographic and voice transtelephonic monitor-

ing. 2000;139:543-8

Alam M, Wardell J, Andersson E, Samad BA, Nordlander R. Right ventricular function in patients with first myocardial motion and tricuspid annual velocity. 2000;139:710-5

Aldershville J (see Søndergaard et al). 2000;139:667-74 Alexander IH (see McGuire et al). 2000:139:359-70

Al-Khalili F, Svane B, Wamala SP, Orth-Gomér K, Rydén L, Schenck-Gustafsson K. Clinical importance of risk factors and exercise testing for prediction of significant coronary artery stenosis in women recovering from unstable coronary artery disease: the Stockholm Female Coronary Risk Study. 2000;

Al-Khatib SM (see McGuire et al). 2000;139:359-70

Alla F, Briancon S, Juillière Y, Mertes PM, Villemot J-P, Zannad F. Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. 2000; 139:895-904

Amarenco P (see Topol et al). 2000;139:927-33 Amidi M (see Zacharski et al). 2000;139:337-45 Anderson KP. (see Shusterman et al). 2000;139:126-33 Andersson E (see Alam et al). 2000;139:710-5 Angel J (see Evangelista et al). 2000;139:773-81 Anis AH (see Carere et al). 2000;139:52-8

Anker SD (see Florea et al). 2000;139:913-7 Ansel GM (see Burket et al). 2000;139:64-71

Anstrom KJ (see Peterson et al). 2000;139:198-207

Antman EM, Fox KM. Guidelines for the diagnosis and management of unstable angine and non-Q-wave myocardial infarction: proposed revisions. 2000;139:461-75

Antoniucci D (see Bolognese et al). 2000;139:153-63

Apstein CS. Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduced injury. 2000;139: S107-S114

Arakawa N (see Nakamura et al). 2000;139:661-6 Arbustini E, Morbini P. 2000;139:926-8 (Reply)

Arch M (see Kaplan et al). 2000;139:378-87

Armstrong PW, Burton JR, Palisaitis D, Thompson CR, de Werf FV, Rose B, Collen D, Teo KK. Collaborative Angiographic Patency Trial of Recomant Staphylokinase (CAPTORS). 2000;139:820-3

Armstrong WF (see Sherman et al). 2000;139:782-7 Arnett DK (see Djoussé et al). 2000;139:704-9 Arnold JMO (see Myers et al). 2000;139:587-95 Arora UK (see Sheifer et al). 2000;139:649-53 Aschermann M (see Lindart et al). 2000;139:1101-8 Ashuri SR (see Espinal et al). 2000;139:1071-6 Asif M (see Dyer et al). 2000;139:297-304 Avelar E (see Sherman et al). 2000;139:782-7 Aysin B (see Shusterman et al). 2000;139:126-33 Azhar G (see Kyne et al). 2000;139:94-100

<sup>9</sup>January, part 1, pp. 1-184; part 2, pp. S1-S28; February, part 1, pp. 185-370; part 2, S29-S60; part 3, S61-S130; March, pp. 371-562; April, pp. 563-744, S131-S210; May, pp. 745-926; June, pp. 927-1113.

B

Babu V (see Cohen et al). 2000;139:734-8 Bahit MC (see McGuire et al). 2000;139:359-70 Bahr RD (see Gurbel et al). 2000;139:320-8

Bailey KR. Clinical trials in acute myocardial infarction: when should we adjust for baseline characteristics? 2000;139:761-3 (Editorial)

Bailey SR (see Wilensky et al). 2000;139:1061-70 Bardy GH (see Marrouche et al). 2000;139:e6 Barr A(see Myers et al). 2000;139:587-95

Barsness GW, Buller C, Ohman EM, Schechter E, Pucillo A, Taylor MA, Miller MJ, Reiner JS, Churchill D, Chandler AB, Gonzales M, Smith J, Tommaso C, Berdan LG, Wildermann NM, Hasdal D, Holmes Jr DR. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. 2000;139:824-9

Bart BA (see Granger et al). 2000;139:609-17

Bartorelli AL (see Wilensky et al). 2000;139:1061-70

Baruch A (see Harris et al). 2000;139:405-11

Bashein G (see Kaplan et al). 2000;139:378-87 Bashore TM (see Leape et al). 2000;139:106-13

Battle J (see McGuire et al). 2000;139:359-70

Battle RW, Crumb S, Tischler MD. Hemodynamic characteristics of congenital aortic stenosis: a quantitative stress echocardiography study. 2000;139:345-51

Bax JJ (see Elhendy et al). 2000;139:224-300 Bech F (see Zacharski et al). 2000;139:337-45 Becker HF (see Koehler et al). 2000;39:142-8 Becker RC (see Singer JO). 2000;139:560-1 Belew K (see Cohen et al). 2000;139:734-8 Bell MR (see Rihal et al). 2000;139:1032-8

Bell MR (see Zacharski et al). 2000;139:337-45 Bellin D (see Meyers et al). 2000;139:78-84

Benjamin EJ (see Vasan et al). 2000;139:412-22 Berdan LG (see Barsness et al). 2000;139:824-9

Berger AK, Radford MJ, Krumholz HM. Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: analysis of the Cooperative Cardiovascular Project. 2000;139:985-92

Berger PB (see Rihal et al). 2000;139:1032-8 Bergerone S (see Brscic et al). 2000;139:979-84 Berk M (see Udelson et al). 2000;139:503-10 Bernabei R (see Gambassi et al). 2000;139:85-93 Bertel O (see Kurz et al). 2000;139:476-81 Betriu A (see Brener et al). 2000;139:476-81

Bianchi A (see Rizzo et al). 2000;139:529-36
Bittner V, Simon JA, Fong J, Blumenthal RS, Newby K, Stefanick ML. Correlates of high HDL cholesterol among women with coronary heart disease. 2000:139:288-96

Bittner V (see Konstam et al). 2000;139:1081-7 Blackhouse G (see O'Brien et al). 2000;139:423-8

Blumenthal RS. Statins: effective antiatherosclerotic therapy. 2000;139:577-83

Blumenthal RS (see Bittner et al). 2000;139:288-96 Boldi E (see Metra et al). 2000;139:511-21

Bolognese L, Buonamici P, Cerisano G, Santini A, Carrabba N, Santoro GM, Antoniucci D, Fazzini PF. Early dobutamine echocardiography predicts improvement in regional and global left ventricular function after reperfused acute myocardial infarction without residual stenosis of the infarct-related artery. 2000;139:153-63

Bolson EL (see Kaplan et al). 2000;139:378-87 Bond BR (see Dorman et al). 2000;139:522-8 Bossuyt PMM (see Steyerberg et al). 2000;139:745-51 Botvinick EH (see Redberg et al). 2000;139:739-44 Bourge RC (see Cuffe et al). 2000;139:15-22 Bremerich J (see Myers et al). 2000;139:252-61

Bremner WF, Sothern RB, Kanabrocki EL, Ryan M, McCormick JB, Dawson S, Connors ES, Rothschild R, Third JLC, Vahed S,

# **Author index\***

### A

Abbottsmith CW (see Kereiakes et al). 20% 139:S53-S60 Abramson MA (see Roe et al). 2000;139:945-51 Acker MA (see DeNofrio et al). 2000;139:729-33

Adams KF (see Cuffe et al). 2000;139:15-22 Ades PA, Pashkow FJ, Fletcher G, Pina IL, Zohman LR, Nestor JR. A controlled trial of cardiac rehabilitation in the home setting using electrocardiographic and voice transtelephonic monitor-

ing. 2000;139:543-8

Alam M, Wardell J, Andersson E, Samad BA, Nordlander R. Right ventricular function in patients with first myocardial motion and tricuspid annual velocity. 2000;139:710-5

Aldershville J (see Søndergaard et al). 2000;139:667-74 Alexander IH (see McGuire et al). 2000:139:359-70

Al-Khalili F, Svane B, Wamala SP, Orth-Gomér K, Rydén L, Schenck-Gustafsson K. Clinical importance of risk factors and exercise testing for prediction of significant coronary artery stenosis in women recovering from unstable coronary artery disease: the Stockholm Female Coronary Risk Study. 2000;

Al-Khatib SM (see McGuire et al). 2000;139:359-70

Alla F, Briancon S, Juillière Y, Mertes PM, Villemot J-P, Zannad F. Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. 2000; 139:895-904

Amarenco P (see Topol et al). 2000;139:927-33 Amidi M (see Zacharski et al). 2000;139:337-45 Anderson KP. (see Shusterman et al). 2000;139:126-33 Andersson E (see Alam et al). 2000;139:710-5 Angel J (see Evangelista et al). 2000;139:773-81 Anis AH (see Carere et al). 2000;139:52-8

Anker SD (see Florea et al). 2000;139:913-7 Ansel GM (see Burket et al). 2000;139:64-71

Anstrom KJ (see Peterson et al). 2000;139:198-207

Antman EM, Fox KM. Guidelines for the diagnosis and management of unstable angine and non-Q-wave myocardial infarction: proposed revisions. 2000;139:461-75

Antoniucci D (see Bolognese et al). 2000;139:153-63

Apstein CS. Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduced injury. 2000;139: S107-S114

Arakawa N (see Nakamura et al). 2000;139:661-6 Arbustini E, Morbini P. 2000;139:926-8 (Reply)

Arch M (see Kaplan et al). 2000;139:378-87

Armstrong PW, Burton JR, Palisaitis D, Thompson CR, de Werf FV, Rose B, Collen D, Teo KK. Collaborative Angiographic Patency Trial of Recomant Staphylokinase (CAPTORS). 2000;139:820-3

Armstrong WF (see Sherman et al). 2000;139:782-7 Arnett DK (see Djoussé et al). 2000;139:704-9 Arnold JMO (see Myers et al). 2000;139:587-95 Arora UK (see Sheifer et al). 2000;139:649-53 Aschermann M (see Lindart et al). 2000;139:1101-8 Ashuri SR (see Espinal et al). 2000;139:1071-6 Asif M (see Dyer et al). 2000;139:297-304 Avelar E (see Sherman et al). 2000;139:782-7 Aysin B (see Shusterman et al). 2000;139:126-33 Azhar G (see Kyne et al). 2000;139:94-100

<sup>9</sup>January, part 1, pp. 1-184; part 2, pp. S1-S28; February, part 1, pp. 185-370; part 2, S29-S60; part 3, S61-S130; March, pp. 371-562; April, pp. 563-744, S131-S210; May, pp. 745-926; June, pp. 927-1113.

B

Babu V (see Cohen et al). 2000;139:734-8 Bahit MC (see McGuire et al). 2000;139:359-70 Bahr RD (see Gurbel et al). 2000;139:320-8

Bailey KR. Clinical trials in acute myocardial infarction: when should we adjust for baseline characteristics? 2000;139:761-3 (Editorial)

Bailey SR (see Wilensky et al). 2000;139:1061-70 Bardy GH (see Marrouche et al). 2000;139:e6 Barr A(see Myers et al). 2000;139:587-95

Barsness GW, Buller C, Ohman EM, Schechter E, Pucillo A, Taylor MA, Miller MJ, Reiner JS, Churchill D, Chandler AB, Gonzales M, Smith J, Tommaso C, Berdan LG, Wildermann NM, Hasdal D, Holmes Jr DR. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. 2000;139:824-9

Bart BA (see Granger et al). 2000;139:609-17

Bartorelli AL (see Wilensky et al). 2000;139:1061-70

Baruch A (see Harris et al). 2000;139:405-11

Bashein G (see Kaplan et al). 2000;139:378-87 Bashore TM (see Leape et al). 2000;139:106-13

Battle J (see McGuire et al). 2000;139:359-70

Battle RW, Crumb S, Tischler MD. Hemodynamic characteristics of congenital aortic stenosis: a quantitative stress echocardiography study. 2000;139:345-51

Bax JJ (see Elhendy et al). 2000;139:224-300 Bech F (see Zacharski et al). 2000;139:337-45 Becker HF (see Koehler et al). 2000;39:142-8 Becker RC (see Singer JO). 2000;139:560-1 Belew K (see Cohen et al). 2000;139:734-8 Bell MR (see Rihal et al). 2000;139:1032-8

Bell MR (see Zacharski et al). 2000;139:337-45 Bellin D (see Meyers et al). 2000;139:78-84

Benjamin EJ (see Vasan et al). 2000;139:412-22 Berdan LG (see Barsness et al). 2000;139:824-9

Berger AK, Radford MJ, Krumholz HM. Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: analysis of the Cooperative Cardiovascular Project. 2000;139:985-92

Berger PB (see Rihal et al). 2000;139:1032-8 Bergerone S (see Brscic et al). 2000;139:979-84 Berk M (see Udelson et al). 2000;139:503-10 Bernabei R (see Gambassi et al). 2000;139:85-93 Bertel O (see Kurz et al). 2000;139:476-81 Betriu A (see Brener et al). 2000;139:476-81

Bianchi A (see Rizzo et al). 2000;139:529-36
Bittner V, Simon JA, Fong J, Blumenthal RS, Newby K, Stefanick ML. Correlates of high HDL cholesterol among women with coronary heart disease. 2000:139:288-96

Bittner V (see Konstam et al). 2000;139:1081-7 Blackhouse G (see O'Brien et al). 2000;139:423-8

Blumenthal RS. Statins: effective antiatherosclerotic therapy. 2000;139:577-83

Blumenthal RS (see Bittner et al). 2000;139:288-96 Boldi E (see Metra et al). 2000;139:511-21

Bolognese L, Buonamici P, Cerisano G, Santini A, Carrabba N, Santoro GM, Antoniucci D, Fazzini PF. Early dobutamine echocardiography predicts improvement in regional and global left ventricular function after reperfused acute myocardial infarction without residual stenosis of the infarct-related artery. 2000;139:153-63

Bolson EL (see Kaplan et al). 2000;139:378-87 Bond BR (see Dorman et al). 2000;139:522-8 Bossuyt PMM (see Steyerberg et al). 2000;139:745-51 Botvinick EH (see Redberg et al). 2000;139:739-44 Bourge RC (see Cuffe et al). 2000;139:15-22 Bremerich J (see Myers et al). 2000;139:252-61

Bremner WF, Sothern RB, Kanabrocki EL, Ryan M, McCormick JB, Dawson S, Connors ES, Rothschild R, Third JLC, Vahed S,

Nemchausky BA, Shirazi P, Olwin JH. Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men. 2000;139:164-73

Brener SJ, Ellis SG, Sapp SK, Betriu A, Granger CB, Burchenal JEB, Moliterno DJ, Califf RM, Topol EJ. Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. 2000;139:476-81

Breningstall GN (see Pierpont et al). 2000;139:S96-S106 Brewster PS (see Burket et al). 2000;139:64-71

Briancon S (see Alla et al). 2000;139:895-904 Briancon S (see Echemann et al). 2000;139:624-31

Brode S (see Shusterman et al). 2000;139:126-33 Broderick T (see Kereiakes et al). 2000;139:553-S60 Brook RH (see Leape et al). 2000;139:106-13

Brotons C (see Evangelista et al). 2000;139:773-81

Brscic E, Bergerone S, Gagnor A, Colajanni E, Matullo G, Scaglione L, Cassader M, Gashino G, Di Leo M, Brusca A, Pagano GF, Piazza A, Trevi GP Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. 2000;139:979-84

Brusca A (see Brscic et al). 2000;139:979-84

Bucher TA (see Wilensky et al). 2000;139:1061-70
Buckley RS, Kaul S, Jayaweera AR, Gimple LW, Powers ER, Dent JM. Quantification of mitral regurgitation in the cardiac catheterization laboratory with contrast chocardiography. 2000;139:1109-13

Buist NRM (see Winter et al). 2000;139:863-869 Buller C (see Barsness et al). 2000;139:824-9 Buller CEH (see Carere et al). 2000;139:52-8 Bultas J (see Lindart et al). 2000;139:1101-8 Buonamici P (see Bolognese et al). 2000;139:153-63

Burchenal JEB (see Brener et al). 2000;139:476-81Burger AJ, Sherman HB, Charlamb MJ. Low incidence of embolic strokes with atrial septal aneurysms: a prospective, long-term study. 2000;139:149-52

Burket MW, Cooper CJ, Kennedy DJ, Brewster PS, Ansel GM, Moore JA, Venkatesan J, Henrich WL. Renal artery angioplasty and stent placement: predictors of a favorable outcome. 2000; 139-64-71

Burnette JS (see Dorman et al). 2000;139:522-8 Burns JC (see Moran et al). 2000;139:217-23 Burton JR (see Armstrong et al). 2000;139:820-3 Buser P (see Myers et al). 2000;139:252-61 Bydlowski SP (see Lopes et al). 2000;139:618-23

#### C

Caldwell MA, Froelicher ES, Drew BJ. Prehospital delay time in acute myocardial infarction: an exploratory study on relation to hospital outcomes and cost. 2000;139:788-96

Califf, RM (see Cuffe et al). 2000;139:15-22 Califf R, Shah M. Introduction. 2000;139:S131-S132

Califf R (see Topol et al). 2000;139:927-33
Califf RM, Cohn JN. Cardiac protection: evolving role of angiotensin receptor blockers. 2000;139:S15-S22

Califf RM. Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. 2000;139:S33-S37

Califf RM (see Cohen et al). 2000;139:962-70 Califf RM (see Brener et al). 2000;139:476-81 Califf RM (see Gent et al). 2000;139:5182-5188 Califf RM (see Granger et al). 2000;139:690-17 Califf RM (see Hasdai et al). 2000;139:858-66 Calvo F (see Evangelista et al). 2000;139:773-81 Camargo Jr CA (see Lloyd-Jones et al). 2000;139:867-73 Campana C (see Lucreziotti et al). 2000;139:1088-95 Campbell SV (see Rizzo et al). 2000;139:529-36 Canos MR (see Sheifer et al). 2000;139:59-63 Canos MR (see Sheris et al). 2000;139:59-63 Cantor WJ (see McGuire et al). 2000;139:359-70 Capomolla S, Febo O, Gnemmi M, Riccardi G, Opasich C,

Caporotondi A, Mortara A, Pinna GD, Cobelli F, β-Blockade therapy in chronic heart failure: distolic function and mitral regurgitation improvement by carvediol. 2000;139:597-617 Caporotondi A (see Capomolla et al., 2000;139:597-617)

Carere RG, Webb JG, Buller CEH, Wilson M, Rahman T, Spinelli J, Anis AH. Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge. 2000;139:52-8

Carmenini G (see Rizzo et al). 2000;139:529-36
Carnegie NM (see Zacharski et al). 2000;139:337-45
Carrabba N (see Bolognese et al). 2000;139:357-65
Carro E (see Pettersson et al). 2000;139:352-8
Cassader M (see Brscic et al). 2000;139:979-84
Cerisano G (see Bolognese et al). 2000;139:153-63
Chalvidan T (see Deharo et al). 2000;139:1022-9
Chambless LE (see Goff Jr et al). 2000;139:875-80
Chan R (see Holmes et al). 2000;139:23-31
Chan R (see Topol et al). 2000;139:927-33

Chandler AB (see Barsness et al). 2000;139:824-9 Chang G (see DeNofrio et al). 2000;139:729-33 Charbonneau L (see Myers et al). 2000;139:587-95

Charlamb MJ (see Burger et al). 2000;139:149-52 Chen Y-T (see Krumholz et al). 2000;139:72-7 Chepurko L (see Katz et al). 2000;139:44-51 Cheriparambil KM (see Kozer et al). 2000:139:134-41

Chol JW, Vardi GM, Meyers SN, Parker MA, Goodreau LM, Davidson CJ. Role of intracoronary ultrasound after high-pressure stent implantation. 2000;139:643-8

Chol JW, Vardi GM, Meyers SN, Parker MA, Goodreau LM, Davidson CJ. Role of intracoronary ultrasound after high-pressure stent implantation. 2000;139:643-8

Chow B (see Zacharski et al). 2000;139:337-45 Churchill D (see Barsness et al). 2000;139:824-9

Ciampricotti B, Schotborgh CE, de Kam P-J, van Herwaarden RH. A comparison of nicorandil with isosobide mononitrate in elderly patients with stable coronary heart disease: the SNAPE study. 2000;139:e3

Claroni S. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. 2000;139:814-9

Coats AJS (see Florea et al). 2000;139:913-7 Cobelli F (see Capomolla et al). 2000;139:597-617 Codd MB (see Mahan et al). 2000;139:311-9

Cohen JD, Drury JH, Ostdiek J, Finn J, Babu V, Flaker G, Belew K, Donohue T, Labovitz A. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events? 2000:139:734-8

Cohen M, Dawson MS, Kopistansky C, McBride R. Sex and other predictors of intra-aortic balloon counterpulsation-related complications: prospective study of 1119 consecutive patients. 2000;139:282-7

Cohen M, Stinnett SS, Weatherly BD, Gurfinkel EP, Fromell GJ, Goodman SG, Fox KAA, Califf RM. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with comination antithrombotic therapy. 2000:139:962-70

Cohen M (see O'Brien et al). 2000;139:423-8 Cohen MC (see Weissman et al). 2000;139:399-404 Cohn JN (see Califf et al). 2000;139:5\s15-\s22 Colajanni E (see Brscic et al). 2000;139:979-84 Colan SD (see Grenier et al). 2000;139:866-895 Colan SD (see Moran et al). 2000;139:217-23 Colonna P, Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. 2000;139:S124-S130

Collen D (see Armstrong et al). 2000;139:820-3

Colucci W (see Cuffe et al). 2000;139:15-22

Connolly SJ. Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. 2000;139:753-60

Connors ES (see Bremner et al). 2000;139:164-73

Conover CJ (see Sloan et al). 2000;139:567-76

Cook JR (see Pinski et al). 2000;139:804-13

Cooper CJ (see Burket et al). 2000;139:64-71

Cooper LS (see Goff Jr et al). 2000;875-80

Corey GR (see Roe et al). 2000;139:945-51 Cox GF (see Grenier et al). 2000;139:S86-S95

Craft L (see Holt et al). 2000;139:537-42

Croft JB (see Ford et al). 2000;139:371-7

Croft JB (see Giles et al). 2000;139:446-53

Crumb S (see Battle et al). 2000;139:346-51

Császár A (see Szombathy et al). 2000;139:101-5

Cuffe MS, Califf RM, Adams KF, Bourge RC, Colucci W, Massie B, O'Connor CM, Pina I, Quigg R, Silver M, Robinson LA, Leimberger JD, Gheorghiade M. Rationale and design of the OPTIME CHF trial: outcomes of a Prospective Trial of Intravenous Milrionone for Exacerbations of Chronic Heart Failure. 2000;139:15-22

Curtis AB, Kutalek SP, Prior M, Newhouse TT. Prevalence and characteristics of escape rhythms after radiofrequency ablation of the atrioventricular junction: results from the Registry for AV Junction Ablation and Pacing in Atrial Fibrillation. 2000;139:

122-5

Cwajg J, Xie F, O'Leary E, Kricksfeld D, Dittrich H, Porter TR. Detection of angiographically significant coronary artery disease with accelerated intermittent imaging after intravenous administration of ultrasound contrast material. 2000;139: 675-83

#### D

Dæ MW (see Redberg et al). 2000;139:739-44

D'Agostino RB, Russell MW, Huse DM, Ellison C, Silbershatz H, Wilson PWF, Hartz SC. Primary and subsequent coronary risk appraisal: new results from The Framingham Study. 2000;139: 272-81

Dalen JE (see Thompson CA). 2000;139:1014-21

Dalesandro MR (see Gurbel et al). 2000;139:320-8

D'Aloia A (see Metra et al). 2000;139:511-21

Damaraju L (see Mascelli et al). 2000;139:696-703

Davidson CJ (see Chol et al). 2000;139:643-48

Davidson CJ (see Leape et al). 2000;139:106-13

Davis S (see Topol et al). 2000;139:927-33 Dawson MS (see Cohen et al). 2000;139:282-7

Dawson S (see Bremner et al). 2000;139:164-73

de Champlain J (see Myers et al). 2000;139:587-95

de Kam P-J (see Ciampricotti et al). 2000;139:e3

de Silva ER (see Ellis et al). 2000:139:1046-53

de Vries RJM, van Veldhuison DJ, Dunselman PHJM. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. 2000; 139:185-94

de Werf FV (see Armstrong et al). 2000;139:820-3

DeAbate C (see Udelson et al). 2000;139:503-10

Deely MP (see Marchlinsk et al). 2000;139:1009-13

Deharo J-C, Peyre J-P, Chalviden T, Thirion X, Valli M, Ritter P, Djiane P. Continuous monitoring of an endocardial index of myocardial contractility during head-up tilt test. 2000;139: 1022-9

Dei Cas I. (see Metra et al). 2000;139:511-21

Deitcher SR (see Murray et al). 2000;139:e5

del Castillo HG (see Evangelista et al). 2000;139:773-81

DeMets DL. Design of phase II trials in congestive heart failure. 2000:139:S207-S210

Deno DC (see Nanthakumar et al). 2000;139:797-803

DeNofrio D, Desai S, Rader DJ, Chang G, Kelley MP, Acker MA, Loh E. Changes in lipoprotein(a) concentration after orthotopic heart transplantation. 2000;139:729-33

Dent J (see Talreja et al). 2000;139:394-8

Dent JM (see Buckley et al). 2000;139:1109-13

Dent JM (see Lindner et al). 2000;139:231-40

Desai S (see DeNofrio et al). 2000;139:729-33

Devereux RB. Therapeutic options in minimizing left ventricular hypertrophy. 2000;139:S9-S14

Di Leo M (see Brscic et al) 2000;139:979-84

Di Maio F (see Rizzo et al). 2000;139:529-36

Di Tullio MR, Sacco RL, Savoia MT, Sciacca RR, Homma S. Aortic atheroma morphology and the risk of ischemic stroke in a multiethnic population. 2000;139:329-36

Diener HC (see Topol et al). 2000;139:927-33

Ding Z-P (see Lau K-W et al). 2000;139:830-9

Dirschinger J (see Kastrati et al). 2000;139:208-16

DiTommaso MA (see Zacharski et al). 2000;139:337-45

Dittrich H (see Cwajg et al). 2000;139:675-83

Djiane P (see Deharo et al). 2000;139:1022-9

Djoussé L, Pankow JS, Arnett DK, Zhang Y, Hong Y, Province MA, Ellison RC. Alcohol consumption and plasminogen activator inhibitor type 1: the National Heart, Lung, and Blood Institute Family Heart Study. 2000;139:704-9

Do D (see Myers et al). 2000;139:78-84

Doevendans PA (see Wehrens et al). 2000;139:430-6

Donohue T (see Cohen et al). 2000;139:734-8

Dorian P (see Nanthakumar et al). 2000;139:797-803
Dorman RH, Sade RM, Burnette JS, Wiles HB, Pinosky ML, Reeves ST, Bond BR, Spinale FG. Magnesium supplementation in the prevention of arrhythmias in pediatric patients undergoing surgery for congenital heart defects.
2000:139:522-8

Drew BJ (see Caldwell et al). 2000;139:788-96

Drury JH (see Cohen et al). 2000;139:734-8

Dubach P (see Myers et al). 2000;139:252-61

Dukas L (see Kyne et al). 2000;139:94-100 Dunselman PHJM (see deVries et al). 2000;139:185-94

Duyser E, Asif M, Ippolito T, Gillespie M. Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries. 2000;139:297-304

Dyke CK (see McGuire et al). 2000;139:359-70

Dzeikan G (see Myers et al). 2000;139:252-61

#### E

East MA, Peterson ED. Understanding racial differences in cardiovascular care and outcomes: issues for the new millennium. 2000;139:764-6 (Editorial)

East MA (see McGuire et al). 2000;139:359-70 Easton JD (see Topol et al). 2000;139:927-33

Echmann M, Zannad F, Briancon S, Juillière Y, Mertès PM, Virion JM, Villemot JP. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. 2000;139:624-31

Edenbrandt L (see Pettersson et al). 2000;139:352-8

Edwards JL (see Harris et al). 2000;139:405-11

Egeland T (see Jørgensen et al). 2000;139:482-90

Eichhorn EJ, Grayburn PA β-Blocker improvement in diastolic performance: the yin and yang of ventricular function changes. 2000;139:584-86 (Editorial)

Elhendy A, von Domburg RT, Bax JJ, Poldermans D, Sozzi FB, Roelandt JRTC. Accuracy of dobutamine technetium 99m ses-

tomibi SPECT imaging for the diagnosis of single-vessel coronary artery disease: comparison with echocardiography. 2000;139:224-230

Elleder M (see Lindart et al). 2000;139:1101-8

Ellenberg SS. Select-drop designs in clinical trials. 2000; 139:S158-S160

Ellis SG, da Silva ER, Spaulding CM, Nobuyoshi M, Welner B, Talley JD. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. 2000;139:1046-53

Ellis SG (see Brener et al). 2000;139:476-81

Ellis ST (see Marso et al). 2000;139:939-44

Ellison C (see D'Agostino et al). 2000;139:272-81

Ellison RC (see Djoussé et al). 2000;139:704-9

Endresen K (see Jørgensen et al). 2000;139:482-90

Epstein AE (see Pinski et al). 2000;139:804-13

Ertl G (see Granger et al). 2000;139:609-17 Escarce JJ (see Sheifer et al). 2000;139:848-57

Espinal M, Fulsz AR, Nanda NC, Asluri SR, Mukhtar O, Sekar PC. Sensitivity and specificity of transesophageal echocardiography for determination of aortic valve morphology. 2000;139:1071-6

Eto G (see Kawano et al). 2000;139:654-60

Evangelista A, del Castillo HG, Calvo F, Permanyer-Miralda G, Brotons C, Angel J, González-Alujas T, Tornos P, Soler-Soler J. Strategy for optimal aortic regurgitation quantification by Doppler echocardiography: agreement among different methods. 2000;139:773-81

### F

Fasol R, Lakew F, Wetter S. Mitral repair in patients with a ruptured papillary muscle. 2000;139:549-54

Fasol R. Mitral repair in patients with a ruptured papillary muscial. 2000;139:549-54

Fazzini PF (see Bolognese et al). 2000;139:153-63

Febo O (see Capomolla et al). 2000;139:597-617

Feit F. Percutaneous coronary artery intervention: the last five years and the next five years. 2000;139:195-7 (Editorial)

Feldman AM. Introduction. 2000;139:S61-S62

Fenyvesi T (see Szombathy et al). 2000;139:101-5

Ferguson J (see Topol et al). 2000;139:927-33

Ferguson JJ (see Lindart et al). 2000;139:1101-8

Fineberg N (see Fogel et al). 2000;139:690-5

Finn J (see Cohen et al). 2000;139:734-8

Fisher L. The development of antiarrhythmic drugs. 2000;139: \$200-\$201

Fitrzgerald D (see Topol et al). 2000;139:927-33

Fitzgerald P (see Holmes et al). 2000;139:23-31

Flaker G (see Cohen et al). 2000;139:734-8

Fleming TR. Design and interpretation of equivalence trials. 2000;139:S171-S176

Fleming TR. Surrogate end points in cardiovascular disease trials. 2000;139:S193-S196

Fletcher G (see Ades et al). 2000;139:543-8

Fletcher RD (see Peniston et al). 2000;139:840-7

Florea VG, Henein MY, Anker SD, Francis DP, Gibson DG, Coats AJS. Relation of changes over time in ventricular size and function to those in exercise capacity in patients with chronic heart failure. 2000;139:913-7

Fogel RI, Herre JM, Kopelmann HA, Kowey PR, Trohman RG, Fineberg N, Prystowsky EN. Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias. 2000; 139:690-5

Folsom AR (see Goff Jr et al). 2000;139:875-80 Fong J (see Bittner et al). 2000;139:288-96 Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. 2000;139:371-7

Ford ES (see Giles et al). 2000;139:446-53

Ford T (see Konstam et al). 2000;139:1081-7

Forfang K (see Jørgensen et al). 2000;139:482-90

Forman DE (see Gambassi et al). 2000;139:85-93

Fow KAA (see Cohen et al). 2000;139:78-84 Fox KAA (see Cohen et al). 2000;139:962-70

Fox KM (see Antman et al). 2000;139:902-70

Francis DP (see Florea et al). 2000;139:913-17

Froelicher ES (see Caldwell et al). 2000;139:788-96

Froelicher V (see Myers et al). 2000;139:252-61

Fromell GJ (see Cohen et al). 2000;139:962-70

Fuchs D (see Ledochowski et al). 2000;139:925-6

Fulsz AR (see Espinal et al). 2000;139:1071-6

Funch-Brentano C, Lancar R, Le Heuzey J-Y, Lardoux H, Soubrié C, Lechat P. Predictors of medical events in patients enrolled in the Cardiac Insufficiency Bisoprolol Study (CIBIS): a study of the interactions between β-blocker therapy and occurrence of critical events using analysis of competitive risks. 2000;139: 262-71

## G

Gagnor A (see Brscic et al). 2000;139:979-84

Gallant P (see Wilensky et al). 2000;139:1061-70

Gambassi G, Forman DE, Lapane KL, Mor V, Sgadari A, Lipsitz LA, Bernabei R. Management of heart failure among very old persons living in long-term care: has the voice of trials spread? 2000;139:85-93

Garratt KN (see Rihal et al). 2000;139:1032-8

Gaschino G (see Brscic et al). 2000;139:979-84

Gattis WA (see O'Connor et al). 2000;139:S143-S154 Gavazzi A (see Lucreziotti et al). 2000;139:1088-95

Gent M, Califf RM. Chronic ischemic heart disease.

2000;139:S182-S188 Gersh BJ (see Sheifer et al). 2000;139:649-53

Gheorghiade M (see Cuffe et al). 2000;139:049-33

Ghio S (see Lucreziotti et al). 2000;139:1088-95

Gibbons RJ When not doing tests is the right thing to do. 2000; 139:388-89 (Editorial)

Gibson DG (see Florea et al). 2000;139:913-7

Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ.

Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: results from the Third National Health and Nutrition Examination Survey. 2000;139:446-53

Giles WH (see Ford et al). 2000;139:371-7

Gilkerson J (see Nanthakumar et al). 2000;139:797-803

Gillespie M (see Dyer et al). 2000;139:297-304

Gilon D, Leitersdorf IL, Gotsman MS, Zahger D, Sapoznikov D, Weiss AT. Reduction of congestive heart failure symptoms by very early fibrinolytic therapy in acute myocardial infarction: a long-term follow-up. 2000;139:1096-1100

Gimple LW (see Buckley et al). 2000;139:1109-13

Giuliano RP (see Lloyd-Jones et al). 2000;139:867-73

Gnemmi M (see Capomolla et al). 2000;139:597-617

Goebbels U (see Myers et al). 2000;139:252-61

Goeree R (see O'Brien et al). 2000;139:423-8

Goff Jr DC, Howard G, Wang C-H, Folsom AR, Rosamond WD, Cooper LW, Chambless LE. 2000;139:874-80

Goldberg RJ. Monitoring trends in severity of acute myocardial infarction: challenges for the next millennium. 2000;139:767-70 (Editorial)

Goldberg RJ (see Thompson et al). 2000;139:1014-21

Goldberg S (see Holmes et al). 2000;139:23-31

Goldman S (see Konstam et al). 2000;139:1081-7

Goldner BG (see Katz et al). 2000;139:44-51

Goncalves RC (see Lopes et al). 2000;139:618-23 Gonzales M (see Barsness et al). 2000;139:824-9 González-Alujas T (see Evangelista et al). 2000;139:773-81 Goodman A (see Murray et al). 2000;139:e5 Goodman S (see O'Brien et al). 2000;139:423-8 Goodman SG (see Cohen et al). 2000;139:962-70 Goodreau LM (see Chol et al). 2000;139:643-8 Gore JM (see Thompson et al). 2000;139:1014-21 Gorwitt J (see Udelson et al). 2000;139:503-10 Gotsman MS (see Gilon et al). 2000;139:1096-1100 Gottipaty V (see Shusterman et al). 2000;139:126-33 Goubadia I (see Rizzo et al). 2000;139:529-36 Gradman A (see Konstam et al). 2000;139:1081-7 Graffagnino C (see Topol et al). 2000;139:927-33 Granett J (see Topol et al). 2000;139:927-33 Granett JR (see Holmes et al). 2000;139:23-31 Granger CB, Ertl G, Kuch J, Maggione AP, McMurray J, Rouleau J-L, Stevenson LW, Swedberg K, Young J, Yusuf S, Califf RM, Bart, BA, Held P, Michelson EL, Sellers MA, Ohlin G, Sparapani R, Pfeffer MA. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. 2000;139:609-17

Granger CB, Skene A. Acute ischemic heart disease. 2000;139: S189-S192 Granger CB (see Brener et al). 2000;139:476-81

Granger CB When is angina good? Preconditioning in acute myocardial infarction. 2000;139:771-2 (Editorial) Grayburn PA (see Eichhorn et al). 2000;139:584-6

Green SJ (see Katz et al). 2000;139:44-51

Greenberg A (see Wilensky et al). 2000;139:1061-70 Greene L (see Pinski et al). 2000;139:804-13

Greene M (see Nanthakumar et al). 2000;139:797-803 Greenfield, Jr JC. Increase in ST-segment elevation immediately after reperfusion: cause and meaning. 2000;139:390-1

(Editorial) Greenlund KJ (see Giles et al). 2000;139:446-53

Grenier MA, Osganian SK, Cox GF, Towbin JA, Colan SD, Lurie PR, Sleeper LA, Orav EJ, Lipshultz SE. Design and implementation of the North American Pediatric Cardiomyopathy Registry. 2000;139:S86-S95

Grill DE (see Rihal et al). 2000;139:1032-8 Grimm RA (see Murray et al). 2000;139:e5 Grimm W (see Koehler et al). 2000;139:142-8 Grossman PM (see Sherman et al), 2000; 139:782-7 Gruver C (see Talreja et al). 2000;139:394-8 Gullestad L (see Meyers et al). 2000;139:78-84 Gunderson B (see Nanthakumar et al). 2000;139:797-803

Gurbel PA, Kereiakes DJ, Dalesandro MR, Bahr RD, O' Connor CM, Serebruany VL. Role of soluble and platelet-bound Psectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. 2000;139:320-8

Gurfinkel EP (see Cohen et al). 2000;139:962-70 Gurm HS (see Marso et al). 2000;139:939-44

Gyamlani G, Parkh C, Kulharni AG. Benefits of magnesium in acute myocardial infarction: timing is crucial. 2000;139:e2

Hack TC (see Weissman et al). 2000;139:399-404 Hall C (see Myers et al). 2000;139:587-95 Hallett Jr, JW (see Spittell et al). 2000;139:241-4 Harrington R (see Topol et al). 2000;139:927-33 Harrington RA (see Hasdal et al). 2000;139:858-66 Harris CW, Edwards JL, Baruch A, Riley WA, Pusser BE, Rejeski WJ, Herrington DM. Effects of mental stress on brachial artery flow-mediated vasodilation in healthy normal individuals. 2000;139:405-11

Harrison JK (see Leape et al), 2000;139:106-13 Hartz SC (see D'Agostino et al). 2000;139:272-81 Hasdai D, Holmes Jr, DR, Criger DA, Topol EJ, Califf RM, Harrington RA. Age and outcome after acute coronary syndromes without persistent ST-segment elevation. 2000;139:

Hasdal D (see Barsness et al). 2000;139:824-9 Hattori R (see Yasue et al). 2000;139:e4 Hausdorff JM (see Kyne et al). 2000;139:94-100 Heidland UE, Heintzen MP, Michel CJ, Strauer B. Adjunctive intracoronary dipridamole in the interventional treatment of small coronary arteries: a prospetively randomized trial. 2000;139:1039-45

Heinle SK (see Roe et al). 2000;139:945-51 Heintzen MP (see Heidland et al). 2000;139:1039-45 Heitman J (see Koehler et al). 2000;139:142-8 Held P (see Granger et al). 2000;139:609-17 Henein MY (see Florea et al). 2000;139:913-7 Heng D (see Nanthakumar et al). 2000;139:797-803 Henrich WL (see Burket et al). 2000;139:64-71 Herre JM (see Fogel et al). 2000;139:690-5 Herrington DM (see Harris et al). 2000:139:405-11 Hilderbrandt P (see Søndergaard et al). 2000;139:667-74

Hiramori K (see Nakamura et al). 2000;139:661-6 Hirota Y (see Suwa et al). 2000;139:905-12

Hodis HN (see Mack et al). 2000;139:993-9 Hoit BD, Suresh DP, Craft L, Walsh RA, Liggett SB.

β<sub>2</sub>-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. 2000;139:537-42

Hojo Y, Ikeda U, Katsuki T, Mizuno O, Shimada K Increased expression of hemostatsis markers in the coronary circulation in patients with coronary artery disease. 2000;139:561-2 (Letter)

Holmes Jr DR (see Barsness et al). 2000;139:824-9 Holmes Jr DR (see Hasdal et al). 2000;139:858-66 Holmes Jr DR (see Rihal et al). 2000;139:1032-8

Holmes D, Fitzgerald P, Goldberg S, LaBlanche J-M, Lincoff AM, Savage M, Serruys P-W, Willerson J, Granett JR, Chan R, Shusterman NH, Poland M. The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: a double-blind placebo-controlled trial. 2000;139:23-31

Homma S (see DiTullio et al). 2000;139:329-36 Hong M-K (see Kim et al). 2000;139:638-42 Hong M-K (see Park et al). 2000 139:e1 Hong Y (see Djoussé et al). 2000;139:704-9 Horwitz RI (see Krumholz et al). 2000;139:72-7 Howard G (see Goff Jr et al). 2000;139:875-80 Howard WL (see Kereiakes et al). 2000;139:S53-S60 Howes PA (see Zacharski et al). 2000;139:337-45 Hrudová J (see Lindart et al). 2000;139:1101-8 Hudson MP (see McGuire et al). 2000;139:359-70 Huse DM (see D'Agostino et al). 2000;139:272-81

Iganashi Y, Ojima K. Lipoprotein(a) in atrial fibrillation. 2000; 139:556 (Reply)

١

Ikeda U (see Hojo et al). 2000;139:561-2 (Reply) Iliceto S (see Colonna et al). 2000;139:S124-S130 Ilson B (see Topol et al). 2000;139:927-33 Inoue H (see Okura et al). 2000;139:716-22

Inserra C (see Lucreziotti et al). 2000;139:1088-95 Ippolito T (see Dyer et al). 2000;139:297-304

Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Ueda K, Noma K, Yumoto A, Nishioka K. Beneficial effect of prodromal angina pectoris is lost in elderly patients with acute myocardial infarction. 2000;139:881-8

Ishii M (see Kawano et al). 2000;139:654-60 Ishikawa K (see Yasue et al). 2000;139:e4

Ishimoto N, Ito M, Kinoshita M. Signal-averaged P-wave abnormalities and atrial size in patients with and without idiopathic paroxysmal atrial fibrillation. 2000:139:684-9

paroxysthat atrial normation. 2000;139:08 Ito M (see Ishimoto et al). 2000;139:684-9 Ito M (see Masuoka et al). 2000;139:305-10 Ito S (see Oki et al). 2000;139:497-502 Ito S (see Wilensky et al). 2000;139:1061-70 Ito T (see Suwa et al). 2000;139:905-12

Itoh S (see Nakamura et al). 2000;139:661-6 Izaguirre R (see Salazar et al). 2000;139:924-5

J

Jadonath R (see Pinski et al). 2000;139:804-13 James PR Effect of pregnancy on the uration of bovine pericar-

dial bioprostheses. 2000;139:924 (Reply) Jánoskúti L (see Szombathy et al). 2000;139:101-5

Jasper E (see Murray et al). 2000;139:e5

Jayaweera AR (see Buckley et al). 2000;139:1109-13 Jenkins PL (see Philbin et al). 2000;139:491-6

Jollis JG (see Kandzan et al). 2000;139:491-6

Joorgensen B, Simonsen S, Endresen K, Forfang K, Egeland T, Thaulow E. Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity. 2000;139:482-90

Jordan RE (see Mascelli et al). 2000;139:696-703 Juillière Y (see Alla et al). 2000;139:895-904 Jullière Y (see Echemann et al). 2000;139:624-31

#### K

Kallikazaros I (see Stefanadis et al). 2000;139:437-45

Kamei S (see Masuoka et al). 2000;139:305-10 Kanabrocki EL (see Bremner et al). 2000;139:64-173

Kandzari DE, Jollis JG Cardiology, for what it's worth. 2000;139: 392-3 (Editorial)

Kaplan AV (see Wilensky et al). 2000;139:1061-70

Kaplan BM (see Katz et al). 2000;139:44-51

Kaplan SR, Bashein G, Sheehan FH, Legget ME, Munt B, Li X-N, Sivarojan M, Bolson EL, Zeppa M, Arch M, Martin RW. Threedimensional echochardiographic assessment of annular shape changes in the normal and regurgitant mitral valve. 2000;139: 378-87

Karetová D (see Lindart et al). 2000;139:1101-8

Kastrati A, Pache J, Dirschinger J, Neumann F-J, Walter H, Schmitt C, Schömig A. Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis. 2000;139:208-16

Kataoka H. Pericardial and pleural effusions in decompensated chronic heart failure. 2000;139:918-23

Kato H (see Kawano et al). 2000;139:654-60

Katoh S (see Masuoka et al). 2000:139:305-10

Katsukawa F (see Kinoshita et al). 2000;139:723-8

Katsuki T (see Hojo et al). 2000;139:561-2 (Reply)

Katz S, Green SJ, Kaplan BM, Chepurko L, Goldner BG, Ong L. Nonrandomized comparison between stent deployment and percutaneous transluminal coronary angioplasty in acute myocardial infarction. 2000;139:44-51

Katz WE (see Murray et al). 2000;139:e5

Kaul S (see Buckley et al). 2000;139:1109-13

Kaul S (see Lindner et al). 2000;139:231-40

Kaul S (see Senior et al). 2000;139:245-51

Kaul S (see Talreja et al). 2000;139:394-8

Kawagoe T (see Ishihara et al). 2000;139:881-8

Kawamura K (see Suwa et al). 2000;139:905-12

Kawano T, Ishil M, Takagi J, Maeno Y, Eto G, Sugahara Y, Toshima T, Yasunaga H, Kawara T, Todo K, Kato H. Threedimensional helical computed tomographic angiography in neonates and infants with complex congential heart disease. 2000;139:654-60

Kawara T (see Kawano et al). 2000;139:654-60

Kawasaki A (see Masuoka et al). 2000;139:305-10

Keane JF (see Marshall et al). 2000;139:1054-60

Kelbæk H (see Søndergaard et al). 2000;139:667-74 Kelley MP (see DeNofrio et al). 2000;139:729-33

Kempler P (see Szombathy et al). 2000;139:101-5

Kennedy DJ (see Burket et al). 2000;139:64-71
Kereiakes DJ, McDonald M, Broderick T, Roth EM, Whang DD, Martin LH, Howard WL, Schneider J, Schimshak T,

Abbottsmith CW. Platelet glycoprotein IIb/IIIa receptor blockers: an appropriate-use model for expediting care in acute coronary syndromes. 2000;139:S53-S60

Kereiakes DJ (see Gurbel et al). 2000;139:320-8

Kiersy C (see Lucreziotti et al). 2000;139:1088-95

Kilgore KS, Lucchesi BR. Neutrophils and altered myocardial function. 2000;139:32-4 (Editorial)

Kim J-J see Kim et al). 2000;139:638-42

Kim J-J (see Park et al). 2000;139:e1 Kim S-W, Hong M-K, Lee CW, Kim, J-J, Park S-W, Park, S-J.

Kim S-W, Hong M-K, Lee CW, Kim, J-J, Park S-W, Park, S-J. Multivessel coronary stenting versus bypass surgery in patients with multivessel coronary artery disease and normal left ventricular function: immediate and 2-year long-term follow-up. 2000;139:638-42

Kinan D (see Konstam et al). 2000;139:1081-7

Kinoshita M (see Ishimoto et al). 2000;139:684-9

Kinoshita N, Mimura J, Obayashi C, Katsukawa F, Onishi S, Yamazaki H. Aortic dilatation among young competitive athletes: echocardiographic screening of 1929 athletes between 15 and 34 years of ago. 2000;139:723-8

Kisslo J (see Roe et al). 2000;139:945-51

Kitamura M (see Masuoka et al). 2000;139:305-10

Kittner SJ (see Giles et al). 2000;139:446-53

Kitzman DW, Wesley DJ. Safety assessment of perflenapent emulsion for echocardiographic contrast enhancement in patients with congestive heart failure of chronic obstructive pulmonary disease. 2000;139:1077-80

Kitzman DW (see Weissman et al). 2000;139:399-404

Klauss V (see Regar et al). 2000;139:623-37

Kleiman NS (see Mascelli et al). 2000;139:696-703

Klein AL (see Murray et al). 2000;139:e5

Knight E (see Kyne et al). 2000;139:94-100 Kobashi A (see Suwa et al). 2000;139:905-12

Kooalshi A (see Suwa et al). 2000;139:905-12
Koehler U, Becker HF, Grimm W, Heitmann J, Peter JH, Schäfer H. Relations among hypoxemia, sleep stage, and bradyarrhythmia during obstructive sleep apnea. 2000;139:

142-8

Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S, Lewis W, Gradman A, Self S, Bittner V, Rand W, Kinan D, Smith JJ, Ford T, Segal R, Udelson JE. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. 2000;139:1081-7

Kopelman HA (see Fogel et al). 2000;139:690-5 Kopistansky C (see Cohen et al). 2000;139:282-7

Koudstall PJ (see Topol et al). 2000;139:927-33

Konstam MA (see Udelson et al). 2000;139:503-10

Kowey PR (see Fogel et al). 2000;139:690-5

Kozer LM, Cheriparambil CM, Schifter DR, Saul BI, Reddy CFR. Clinical significance of variability of ventricular late potentials detedted before discharge in patients after myocardial infarction. 2000;139:134-41

Kricksfeld D (see Cwajg et al), 2000;139:675-83

Krumholz HM, Chen Y-T, Wang Y, Vaccarino V, Radford MJ,

Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. 2000;139:72-

Krumholz HM (see Berger et al). 2000;139:985-92

Kuch J (see Granger et al). 2000;139:609-17 Kukin ML (see Udelson et al). 2000;139:503-10

Kulkarni AG (see Gyamlani et al). 2000;139:e2

Kurz DJ, Naegeli B, Bertel O. A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of postprocedural chest pain and minor myocardial necrosis after elective coronary stenting. 2000:139:35-43

Kutalek SP (see Curtis et al). 2000;39:122-5

Kyne L, Hausdorff JM, Knight E, Dukas L, Azhar G, Wei JY. Neutrophilia and congestive heart failure after acute myocardial infarction. 2000;139:94-100

La Bresh K (see Konstam et al). 2000;139:1081-7 LaBlanche J-M (see Holmes et al). 2000;139:23-31

Labovitz A (see Cohen et al). 2000;39:734-8

Lahiri A (see Senior et al), 2000;139:245-51

Lakew F (see Fasol et al). 2000;139:549-54

Lancar R (see Funck-Brentano et al). 2000;139:262-71

Lancaster S (see Pinski et al). 2000;139:804-13 Lansky AJ (see Peterson et al). 2000;139:198-207

Lanzilotta MI (see Peterson et al). 2000;139:198-207

Lapane KL (see Gambassi et al). 2000;139:85-93

LaPointe NMA, Li P. Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series. 2000:139:114-21

Lardoux H (see Funck-Brentano et al). 2000;139:262-71

Larson MG (see Vasan et al). 2000;139:412-22

László Z (see Szombathy et al). 2000;139:101-5

Lau K-W, Ding Z-P, Sim L-L, Sigwart U. Clinical and angiographic outcome after angiography-guided stent placement in small coronary vessels. 2000;139:830-9

Lavori PW (see Zacharski et al). 2000;139:337-45

Le Heuzey J-Y (see Funck-Brentano et al). 2000;139:262-71

Leape LL, Park RE, Bashore TM, Harrison JK, Davidson CJ, Brook RH. Effect of variability in the interpretation of coronary angiograms on the appropriateness of use of coronary revascularization procedures. 2000;139:106-13

Lechat P (see Funck-Brentano et al). 2000;139:262-71

Ledochowski M, Widner B, Fuchs D. Helicobacter pylori and chronic immune activation. 2000;139:925-6 (Letter)

Ledvinová J (see Lindart et al). 2000;139:1101-8

Lee CW (see Kim et al). 2000;139:638-42

Lee CW (see Park et al). 2000;139:e1

Lee KL. Sample size and interim analysis issues for dose selection. 2000;139:S161-S165

Lee KL (see Steyerberg et al). 2000;139:745-51

Lee N-H (see Park et al). 2000;139:e1

Legget ME (see Kaplan et al). 2000;139:378-87

Leimberger JD (see Cuffe et al). 2000;139:15-22

Leitersdorf L (see Gilon et al). 2000;139:1096-1100

LeJentel T (see Udelson et al). 2000;139:503-10

Leon MB (see Wilensky et al). 2000;139:1061-70

Lessard D (see Thompson et al). 2000;139:1014-21

Levine TB (see Udelson et al). 2000;139:503-10

Levy D (see Vasan et al). 2000;139:412-22

Lewis W (see Konstam et al). 2000;139:1081-7

Li J (see Roe et al). 2000;139:945-51

Li P (see LaPointe et al). 2000;139:114-21

Li X-N (see Kaplan et al). 2000;139:378-87

Liggett SB (see Holt et al). 2000;139:537-42

Lincoff AM. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revacularization

in patients with diabetes mellitus: results of the EPISTENT trial. 2000:139:S46-S52

Lincoff AM (see Holmes et al). 2000;139:23-31

Lindner JR, Villaneuva FS, Dent JM, Wei K, Sklenar J, Kaul S. Assessment of resting perfusion with myocardial contrast echocardiography: theoretical and practical considerations. 2000;139:231-40

Linhart A, Paleek T, Bultas J, Ferguson JJ, Hirudová J, Karetová D, Zeman J, Ladvinová J, Poupeovâ H, Elieder M. Aschermann M. New insights in cardiac structural changes in patients with Fabry's disease. 2000;139:1101-8

Lip GYH. Lipoprotein(a) in atrial fibrillation. 2000;139:555-6 (Letter)

Lipicky R. An FDA perspective on antiarrhythmic drugs in phase II trials. 2000;139:S197-S199

Lipshultz SE (see Grenier et al). 2000;139:S86-S95

Lipsitz LA (see Gambassi et al). 2000;139:85-93

Lloyd-Jones DM, Camargo JR, Giuliano RP, O'Donnell CJ. Effect of leukocytosis at initial examination on prognosis inpatients with primary unstable angina. 2000;139:868-73

Lock JE (see Marshall et al). 2000;139:1054-60

Loh E (see DeNofrio et al). 2000;139:729-33

Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. 2000;139:S115-S119

Lopes AA, Maeda NY, Goncalves RC, Bydlowski SP. Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. 2000:139: 618-23

Lorido A (see Rizzo et al). 2000;139:529-36

Lu DY (see Peniston RL). 2000;139:840-7

Lucchesi BR (see Kilgore et al). 2000;139:32-4

Lucreziotti S, Gavazzi A, Scclsi L, Inserra C, Klersy C, Campana C, Ghio S, Vanoli E, Tavazzi L. Five-minute recording of heart rate variability in severe chronic heart failure: correlates with right ventricular function and prognostic implications. 2000;139:1088-95

Lurie PR (see Grenier et al). 2000;139:S86-S95 Lytle BW (see Marso et al). 2000;139:939-44

Mack WJ, Xiang M, Selzer RH, Hodis HN. Serial quantitative coronary angiography and coronary events. 2000;139:993-9

Maeda NY (see Lopes et al). 2000;139:618-23

Maeno Y (see Kawano et al). 2000;139:654-60

Maggioni AP (see Granger et al). 2000:139:609-17 Mahon NG, Codd MB, McKenna CJ, O'Rorke C, McCann HA, Sugrue DD. Characteristics and outcomes in patients with acute myocardial infarction with ST-segment depression on

initial electrocardiagram. 2000;139:311-9 Makita S (see Nakamura et al). 2000;139:661-6

Malden L (see Nanthakumar et al). 2000;139:797-803

Malouf JF (see Murray et al). 2000;139:e5

Marchlinski FE. Sex-specific triggers for right ventricular outflow tract tachyardia. 2000;139:1009-13

Marciniak Jr SJ (see Mascelli et al). 2000;139:696-703

Marinchak RA (see Pinski et al). 2000;139:804-13

Mark DB, Simons TA. Economic end points in phase II trials. 2000;139:S155-S157

Marouche NF, Reddy RK, Wittkowsky AK, Bardy GH. High-dose bolus lidocaine for chemical cardioversion of atrial fibrilaltion: A prospective, randomized, double-blind crossover trial. 2000:139:e6

Marshall AC, Perry SB, Keane JF, Lock JE. Early results and medium-term follow-up of stent implantation for mild residual or recurrent aortic coarctation. 2000;139:1054-60

Marso SP, Ellis SG, Gurm HS, Lytle BW, Topol EJ. Proteinuria is a

key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. 2000;139:939-44

Martin J (see Wilensky et al). 2000;139:1061-70 Martin LH (see Kereiakes et al). 2000;139:S53-S60

Martin RW (see Kaplan et al). 2000;139:378-87
Mascelli MA, Kleiman NS, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. 2000:139:696-703

Massie B (see Cuffe et al). 2000;139:15-22 Masuda Y (see Yasue et al). 2000;139:e4

Masuoka H, Kamei S, Wagayama H, Ozaki M, Kawasaki A, Tanaka T, Kitamura M, Katoh S, Shintani U, Misaki M, Sugawa M, Ito M, Nakano T. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. 2000;139:305-10

Matsuoka M (see Oki et al). 2000;139:497-502 Matullo G (see Brscic et al). 2000;139:979-84 Maynard C (see Pettersson et al). 2000;139:352-8 McBride R (see Cohen et al). 2000;139:282-7

McCann HA (see Mahan et al). 2000;139:311-9

McCormick JB (see Bremner et al). 2000;139:164-73 McDonald M (see Kereiakes et al). 2000;139:S53-S60

McElhinney DB (see Redberg et al). 2000;139:739-44
McGuire DK, Hudson MP, East MA, Dyke CK, Cantor WJ, Battle J, Bahit MC, Al-Khatib SM, Alexander JH. Highlights from the American Heart Association 72nd Scientific Sessions:

November 6 to 10, 1999. 2000;139;359-70

McGuire DK. Influence of proteinuria on long-term outcome among patients with diabetes: the evidence continues to

accumulate. 2000;139:934-5 (Editorial) McKenna CJ (see Mahan et al). 2000;139:311-9 McMurray J (see Granger et al). 2000;139:609-17

Meijs M, Roukema G. Effects of exercise on QT dispersion in ischemic heart. 2000;139:557-8 (Reply)

Mendelsohn FO (see Sheifer et al.). 2000;139:649-53 Mertes P-M (see Alla et al.). 2000;139:895-904 Mertès PM (see Echemann et al.). 2000;139:624-31

Mészáros A (see Szombathy et al). 2000;139:101-5

Metra M, Nodari S, D'Aloia A, Bontempi L, Boldi E, Dei Cas L. A rational for the use of  $\beta$ -blockers as standard treatment for heart failure. 2000;139:511-21

Meyers SN (see Chol et al). 2000;139:643-48
Michel CJ (see Heidland et al). 2000;139:1039-45
Michelson EL (see Granger et al). 2000;139:609-17
Miklósi M (see Szombathy et al). 2000;139:101-5
Miller JM (see Barsness et al). 2000;139:39:824-9
Mimura J (see Kinoshita et al). 2000;139:723-8
Mintz GS (see Wilensky et al). 2000;139:1061-70
Misaki M (see Masuoka et al). 2000;139:305-10
Mishiro Y (see Oki et al). 2000;139:497-502
Misnati S (sea Vincental). 2000;139:497-502

Miyazaki S (see Yasue et al). 2000;139:e4

Mizuno O (see Hojo et al). 2000;139:561-2 (Reply)
Moe GW, Rouleau JL, Charbonneau L, Proulx G, Arnold MO, Hall C, de Champlain J, Barr A, Sirois P, Packer M.
Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flose-quinan. 2000;139:587-95

Moliterno DJ. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. 2000;139:563-6

Moliterno DJ (see Brener et al). 2000;139:476-81 Moore JA (see Burket et al). 2000;139:64-71

Mor V (see Gambassi et al). 2000;139:85-93

Moran AM, Newburger JW, Sanders SP, Parness IA, Spevak PJ, Burns JC, Colan SD. Abnormal myocardial mechanics in Kawasaki disease: rapid response to γ-globulin. 2000;139: 217-23

Morbini P (see Arbustini et al). 2000;139:926-8 (Reply)

Moser M (see Weir et al). 2000;139:174-84
Moses J (see Wilensky et al). 2000;139:1061-70
Motomiya T (see Yasue et al). 2000;139:624
Mudra H (see Regar et al). 2000;139:623-37
Mueller P (see Myers et al). 2000;139:252-61
Muhlbaier LH (see Peterson et al). 2000;139:198-207
Mukhtar O (see Espinal et al). 2000;139:1071-6
Muluk S (see Zacharski et al). 2000;139:37-45
Murt B (see Kaplan et al). 2000;139:378-87
Murdoch D (see Singer et al). 2000;139:558-60 (Reply)
Murray RD, Shah A, Jasper SE, Goodman A, Belcher S, Katz WE,
Malouf JF, Stoddard MF, Grimm RA, Klein AL.
Transesophageal echocardiography guided enoxaparin
antithrombotic strategy for cardioversion of atrial fibrillation:

Mortara A (see Capomolla et al). 2000;139:597-617

the ACUTE II pilot study. 2000;139:e5

Myers J, Goebbels U, Dzeikan G, Froelicher V, Bremerich J,
Mueller P, Buser P, Dubach P. Exercise training and myocardial remodeling in patients with reduced ventricular function: one-year follow-up with magnetic resonance imaging.
2000:139:252-62

Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H, Fowler MB. Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited. 2000;139:78-84

## N

Naegeli B (see Kurz et al). 2000;139:35-43 Nakamura M, Itoh S, Makita S, Ohira A, Arakawa N, Hiramori K.

Nakamura M, Itoh S, Makita S, Ohira A, Arakawa N, Hiramori K. Peripheral resistance vessel dysfunction in Marfan syndrome. 2000;139:661-6

Nakano T (see Masuoka et al). 2000;139:305-10 Nanda NC (see Espinal et al). 2000;139:1071-6

Nanthakumar K, Paquette M, Newman D, Deno DC, Malden L, Gunderson B, Gilkerson J, Greene M, Heng D, Dorian P. Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators. 2000;139:797-803

Naylor CD (see Parker et al). 2000;139:952-61 Nemchausky BA (see Bremner et al). 2000:139:164-73 Nestor JR (see Ades et al). 2000;139:543-8 Neuberg G (see Udelson et al). 2000;139:503-10 Neumann F-J (see Kastrati et al). 2000;139:208-216 Newburger JW (see Moran et al). 2000;139:217-23 Newby K (see Bittner et al). 2000;139:288-96 Newhouse TT (see Curtis et al). 2000;139:122-5 Newman D (see Nanthakumar et al). 2000;139:797-803 Nicklas IM (see Sherman et al). 2000;139:782-7 Nishino M (see Redberg et al). 2000;139:739-44 Nishioka K (see Ishihara et al). 2000;139:881-8 Nishiyama S (see Okura et al), 2000;139:716-22 Nobuyoshi M (see Ellis et al). 2000;139:1046-53 Nodari S (see Metra et al). 2000;139:511-21 Noma K (see Ishihara et al). 2000;139:881-8 Nordlander R (see Alam et al). 2000:139:710-15

## 0

Obayashi O (see Kinoshita et al). 2000;139:723-8 O'Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? 2000;139-423-8

O'Connor CM, Gattis WA, Ryan TJ. The role of clinical nonfatal and points in cardiovascular phase II/III clinical trials. 2000;139:S143-S154 O'Connor CM (see Cuffe et al). 2000;139:15-22 O'Connor CM (see Gurbel et al). 2000;139:320-28 O'Donnell CI (see Lloyd-Jones et al). 2000;139:867-73 Ogawa H (see Yasue et al). 2000;139:e4 Ohira A (see Nakamura et al). 2000;139:661-6 Ohlin G (see Granger et al). 2000;139:609-17

Ohman EM (see Barsness et al), 2000:139:824-9 Oki T. Mishiro Y. Yamada H, Onose Y, Matsuoka M, Wakatsuki T, Tabata T, Ito S. Detection of left ventricular regional relaxation abnormalities and asynchrony in patients with hypertrophic cardiomyopathy with the use of tissue Doppler imaging. 2000;139:497-502

Okura H, Inoue H, Tomon M, Nishiyama S, Yoshikawa T, Yoshida K, Yoshikawa J. Impact of Doppler-derived left ventricular diastolic performance on exercise capacity in normal individuals. 2000;139:716-22

O'Leary E (see Cwajg et al). 2000;139:675-83 Olwin JH (see Bremner et al). 2000;139:164-73 Ong L (see Katz et al). 2000;139:44-51 Onishi S (see Kinoshita et al). 2000;139:723-8 Onose Y (see Oki et al). 2000;139:497-502 Opasich C (see Capomolla et al). 2000;139:597-617 Ophuis TJO (see Wehrens et al). 2000;139:430-6 Oral H (see Sherman et al). 2000;139:782-7 Orav EJ (see Grenier et al). 2000;139:S86-S95 O'Rorke C (see Mahan et al). 2000;139:311-9 Orth-Gomér K (see Al-Khalili et al). 2000;139:971-8 Osganian SK (see Grenier et al). 2000;139:S86-S95 Oshima M (see Tanabe et al). 2000;139:889-4 Ostdiek J (see Cohen et al). 2000;139:734-8 Ozaki M (see Masuoka et al). 2000;139:305-10

Pache J (see Kastrati et al). 2000;139:208-16 Pacifico A (see Pinski et al). 2000:139:804-13 Packer M. Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure. 2000;139:S202-

Packer M (see Moe et al). 2000;139:587-95 Packer M (see Myers J et al). 2000;139:252-61 Packer M (see Udelson et al). 2000;139 503-10 Pagano GF (see Brscic et al). 2000;139:979-84 Pahlm O (see Pettersson et al). 2000;139:352-8 Paleek T (see Lindart et al). 2000;139:1101-8 Palisaitis D (see Armstrong et al). 2000;139:820-3 Pankow IS (see Djoussé et al). 2000;139:704-9 Papademitriou V (see Peniston et al). 2000;139:840-7 Paquette M (see Nanthakumar et al). 2000;139:797-803 Parikh C (see Gyamlani et al). 2000;139:e2 Park RE (see Leape et al). 2000;139:106-13 Park S-J (see Kim et al). 2000;139:638-42 Park S-J (see Park et al). 2000;139:e1

Park S-W, Lee CW, Hong M-K, Kim J-J, Lee N-H, Park S-J. Role of cutting balloon angioplasty before coronary stent implantation. 2000:139:e1

Park S-W (see Kim et al). 2000;139:638-42 Parker AB, Naylor CD. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. 2000; 139:952-61

Parker MA (see Chol et al). 2000;139:643-48 Parness IA (see Moran et al). 2000;139:217-23 Pashkow FJ (see Ades et al). 2000:139:543-8 Patten RD (see Konstam et al). 2000;139:1081-7

Peniston RL, Lu DY, Papademetriou V, Fletcher RD. Severity of coronary artery disease in black and white male veterans and likelihood of revascularization. 2000;139:840-7

Permanyer-Miralda G (see Evangelista et al). 2000;139:773-81

Perry SB (see Marshall et al). 2000;139:1054-60 Peter JH (see Koehler et al). 2000;139:142-8 Peterson ED, Lansky AJ, Anstrom KJ, Muhlbaier LH, Popma JJ, Satler LF, Lanzilotta MJ. Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network database. 2000;139:198-207 Peterson ED (see East et al). 2000:139:764-6 Petretto F (see Rizzo et al). 2000:139:529-36

Pettersson J, Carro E, Edenbrandt L, Maynard C, Pahlm O, Ringborn M, Sörnmo L, Warren SG, Wagner GS. Spatial, individual, and temporal variation of the high-frequency QRS amplitudes in the 12 standard electrocardiagraphic leads. 2000:139:352-8

Peyre J-P (see Deharo et al). 2000;139:1022-9 Pfeffer MA. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers. 2000;139:S23-S28

Pfeffer MA (see Granger et al). 2000;139:609-17 Philbin EF, Jenkins PL. Differences between patients with heart failure treated by cardiologists, internists, family physicians, and other physicians: analysis of a large, statewide database. 2000;139:491-6

Piazza A (see Brscic et al). 2000;139:979-84 Pierpont MEM, Breningstall GN, Stanley CA, Singh A. Familial carnitine transporter defect: a treatable cause of cardiomyopathy in children. 2000;139:S96-S106 Pina I (see Cuffe et al). 2000;139:15-22

Pina IL (see Ades et al). 2000;139:543-8 Pinna GD (see Capomolla et al). 2000;139:597-617 Pinosky ML (see Dorman et al). 2000;139:522-8

Pinski SL, Yao Q, Epstein AE, Lancaster S, Greene L, Pacifico A, Cook JR, Jadonath R, Marinchak RA. Determinants of outcome in patients with sustained ventricular tachyarrhythmias: the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study Registry. 2000;139:804-13

Poland M (see Holmes et al). 2000;139:23-31 Poldermans D (see Elhendy et al). 2000;139:224-300 Popma JJ (see Peterson et al), 2000;139:198-207 Popma JJ (see Wilensky et al). 2000;139:1061-70 Porter TR (see Cwajg et al). 2000;139:675-83 Poupeová H (see Lindart et al). 2000;139:1101-8 Powers ER (see Buckley et al). 2000;139:1109-13 Prior M (see Curtis et al). 2000;139:122-5 Proulx G (see Myers et al). 2000;139:587-95 Province MA (see Djoussé et al). 2000;139:704-9 Prystowsky EN (see Fogel et al). 2000;139:690-5 Pucillo A (see Barsness et al). 2000;139:824-9 Pusser BE (see Harris et al). 2000;39:405-11

Quigg R (see Cuffe et al). 2000;139:15-22

### R

Rader DJ (see DeNofrio et al). 2000;139:729-33 Radford MG (see Berger et al). 2000;139:985-92 Radford MJ (see Krumholz et al). 2000;139:72-7 Rahman T (see Carere et al). 2000;139:52-8 Ramahi T (see Konstam et al) 2000-139-1081-7 Rand W (see Konstam et al). 2000;139:1081-7 Rankin PJ (see Sloan et al). 2000;139:567-76 Redberg RF, Nishino M, McElhinney DB, Dæ MW, Botvinick EH. Long-term estrogen replacement therapy is associated with improved exercise capacity in postmenopausal

women without known coronary artery disease. 2000;139: 739-44

Reddy CVR (see Kozer et al). 2000;139:134-41 Reddy RK (see Marrouche et al). 2000;139:e6

Reeves ST (see Dorman et al). 2000;139:522-8

Regar E, Werner F, Siebert U, Rieber J, Thelsen K, Mudra H, Klauss V. Reproducibility of neointima quantification with motorized intravascular ultrasound pullback in stented coronary arteries. 2000;139:632-7

Reiner JS (see Barsness et al). 2000;139:824-9 Rejeski WJ (see Harris et al). 2000;139:405-11

Riccardi G (see Capomolla et al). 2000;139:597-617 Rieber J (see Regar et al). 2000;139:623-37

Rihal C, Grill DE, Bell MR, Berger PB, Garratt KN, Holmes Jr DR. Prediction of death after percutaneous coronary interventional procedures. 2000;139:1032-8

Riley WA (see Harris et al). 2000;139:405-11 Ringborn M (see Pettersson et al). 2000;139:352-8 Ritter P (see Deharo et al). 2000;139:1022-9

Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. 2000;139:S120-S123

Rizzo V, Di Maio F, Campbell SV, Tallarico D, Petretto F, Lorido A, Bianchi A, Goubadia I, Carmenini G. Left ventricular function, cardiac dysrhythmias, atrial activation, and volumes in nondipper hypertensive individuals with left ventricular hypertrophy. 2000;139:529-36

Robinson LA (see Cuffe et al). 2000;139:15-22

Roe MT, Abramson MA, Li J, Heinle SK, Kisslo J, Corey GR, Sexton DJ. Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocardities by the Duke criteria. 2000;139:945-51

Roelandt JRTC (see Elhendy et al). 2000;139:224-300 Romano M. Effects of exercise on QT dispersion in ischemic

heart disease. 2000;139:556-7 (Letter) Romics L (see Szombathy et al). 2000;139:101-5 Rosamond WD (see Goff Jr et al). 2000; 875-80

Rose B (see Armstrong et al). 2000;139:820-3 Ross H (see Meyers et al). 2000;139:78-84

Roth EM (see Kereiakes et al). 2000;139:S53-S60 Rothschild R (see Bremner et al). 2000;139:164-73 Roukema G (see Meijs et al). 2000;139:557-8

Rouleau J-L (see Granger et al). 2000;139:609-17 Rouleau JL (see Moe et al). 2000;139:587-95

Russell MW (see D'Agostino et al). 2000;139:272-81 Ryan M (see Bremner et al). 2000;139:164-73 Ryan TJ (see O'Connor et al). 2000;139:S143-S154

Ryan TJ (see O'Connor et al). 2000;139:S143-S1 Rydén L (see Al-Khalili et al). 2000;139:971-8

S

Sacco RL (see DiTullio et al). 2000;139:329-36
Sachdev V (see Sherman et al). 2000;139:782-7
Sade RM (see Dorman et al). 2000;139:522-8
Saito M (see Yasue et al). 2000;139:e4
Salazar E, Izaguirre R. 2000;139:924-5 (Reply)
Samad BA (see Alam et al). 2000;139:710-5
Samuels R (see Topol et al). 2000;139:927-33
Sanders SP. Endovascular stent treatment of aortic coarctation. 2000;139:936-8 (Editorial)

Sanders SP (see Moran et al). 2000;139:217-23 Santini A (see Bolognese et al). 2000;139:153-63 Santoro GM (see Bolognese et al). 2000;139:153-63 Sapoznikov D (see Gilon et al). 2000;139:1096-1100 Sapp SK (see Brener et al). 2000;139:476-81 Satler LF (see Peterson et al). 2000;139:198-207 Sato H (see Ishihara et al). 2000;139:881-8 Saul BI (see Kozer et al). 2000;139:134-41 Savage M (see Holmes et al). 2000!138:23-31 Savoia MT (see DiTullio et al). 2000:139:329-36

Scaglione L (see Brscic et al). 2000;139:979-84 Scelsi L (see Lucreziotti et al). 2000;139:1088-95 Schäfer H (see Koehler et al). 2000:139:142-8

Schechter E (see Barsness et al). 2000;139:824-9 Schenck-Gustafsson K (see Al-Khalili et al). 2000;139:971-8

Schifter DR (see Kozer et al). 2000;139:134-41 Schmitt C (see Kastrati et al). 2000;139:208-16

Schneider J (see Kereiakes et al). 2000;139:553-\$60

Schömig A (see Kastrati et al). 2000;139:208-16

Schotborgh CE (see Ciampricotti et al). 2000;139:e3 Schulman KA (see Sheifer et al). 2000;139:848-57

Schwartzman D (see Shusterman et al). 2000;139:126-33

Sciacca RR (see DiTullio et al). 2000;139:329-36 Segal R (see Konstam et al). 2000;139:1081-7

Sekar PC (see Espinal et al). 2000;139:1061-7

Self S (see Konstam et al). 2000;139:1081-7

Sellers MA (see Granger et al). 2000;139:609-17 Selzer RH (see Mack et al). 2000;139:993-9

Senior R. Kaul S, Soman P, Lahiri A. Power Doppler harmonic imaging: a feasibility study of a new technique for the assess-

ment of myocardial perfusion. 2000;139:245-51 Serebruany VI. (see Gurbel et al). 2000;139:320-8 Serruys PW. (see Holmes et al). 2000;139:23-31 Seward JB (see Spittell et al). 2000;139:241-4 Sexton DJ (see Roe et al). 2000;139:945-51 Sgadari A (see Gambassi et al). 2000;139:85-93

Shah A (see Gambassi et al). 2000;139:85-95 Shah M (see Califf et al). 2000;139:e5

Shah M (see Califf et al). 2000;139:S131-S132 Sheehan FH (see Kaplan et al). 2000;139:378-87

Sheifer SE, Escarce JJ, Schulman KA. Race and sex differences in the management of coronary artery disease. 2000;139: 848-57

Sheifer STE, Canos MR, Weinfurt KP, Arora UK, Mendelsohn FO, Gersh BJ, Weissman NJ. Sex differences in coronary artery sized assessed by intravascular ultrasound. 2000;139: 649-53

Sheris SJ, Canos MR, Weissman NJ. Natural history of intravascular ultrasound–detected edge dissections from coronary stent deployment. 2000;139:59-63

Sherman HB (see Burger et al). 2000;139:149-52

Sherman HL, Avelar E, Grossman PM, Sachdev V, Oral H, Nicklas JM, Armstrong WF. Transpulmonary passage of Albunex as a marker of intracardiac hemodynamics and outcome in chronic congestive heart failure. 2000;139: 782-7

Shimada K (see Hojo et al). 2000;139:561-2 (Reply) Shimatani Y (see Ishihara et al). 2000;139:881-8 Shimshak T (see Kereiakes et al). 2000;139:853-860

Shintani U (see Masuoka et al). 2000;139:305-10

Shirazi P (see Bremner et al). 2000;139:164-73 Shualb A (see Topol et al). 2000;139:927-33

Shusterman NH (see Holmes et al). 2000;139:23-31 Shusterman V, Aysin B, Weiss R, Brode S, Gottipaty V.

schwartzman V, Aysin B, Weiss R, Brode S, Gottipaty V, Schwartzman D, Anderson KP. Dynamics of low-frequency R-R interval oscillations preceding spontaneous ventricular achycardia. 2000;139:126-33

Siebert U (see Regar et al). 2000;139:623-37

Siegel JP. Equivalence and noninferiority trials. 2000;139:S166-S170

Sigwart U (see Lau K-W et al). 2000;139:830-9 Silbershatz H (see D'Agostino et al). 2000;139:272-81

Silver M (see Cuffe et al). 2000;139:15-22 Sim L-L (see Lau K-W et al). 2000;139:830-9

Simon JA (see Bittner et al). 2000;139:288-96 Simons TA (see Mark et al). 2000;139:S155-S157

Simonsen S (see Jorgensen et al). 2000;139:482-90

Singer IO. Tait RC. Murdoch D. Low-molecular-weight heparin as optimal solution to therapeutic heparinization. 2000;139:558-60 (Letter)

Singh A (see Pierpont et al). 2000;139:S96-S106 Sirois P (see Myers et al). 2000;139:587-95

Sivarajan M (see Kaplan et al). 2000;139:378-87

Skene A (see Granger et al). 2000;139:S189-S192 Sklenar I (see Lindner et al), 2000:138:231-40

Sklenar J (see Talreja et al). 2000;139:394-8

Sleeper LA (see Grenier et al). 2000;139:S86-S95

Sloan FA, Rankin PJ, Whellan DJ, Conover CJ. Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction. 2000;139:567-76

Smith J (see Barsness et al). 2000;139:824-9

Smith II (see Konstam et al). 2000:139:1081-7 Smith WK (see Udelson et al). 2000;139:503-10

Soler-Soler J (see Evangelista et al). 2000;139:773-81

Soman P (see Senior et al). 2000;139:245-51

Søndergaard L, Aldershville J, Hildebrandt P, Kelbæk H, Stáhlberg F, Thomsen C. Vasodilation with felodipine in chronic asymptomatic aortic regurgitation. 2000;139:667-74.

Sörnnmo L (see Pettersson et al). 2000;139:352-8 Sothern RB (see Bremner et al). 2000;139:164-73

Soubrié C (see Funck-Brentano et al). 2000;139:262-71

Sozzi FB (see Elhendy et al). 2000;139:224-300

Sparapani R (see Granger et al). 2000;139:609-17

Spaulding CM (see Ellis et al). 2000;139:1046-53 Spevak PJ (see Moran et al). 2000;139:217-23

Spinale FG (see Dorman et al). 2000;139:522-8

Spinelli J (see Carere et al). 2000;139:52-8 Spittell PC, Seward JB, Hallet Jr JW. Mobile thrombi in the abdominal aorta in cases of lower extremity embolic arterial occlusion: value

of extended transthorocic echocardiography. 2000;139:241-4 Stáhlberg F (see Søndergaard et al). 2000;139:667-74

Stanley CA (see Pierpont et al). 2000;139:S96-S106 Stefanadis C, Toutouzas K, Tsiamis E, Viachopoulos C,

Kallikazaros I, Stratos C, Vavuranakis M, Toutouzas P. Stents covered by autologous venous grafts: feasibility and immediate and long-term results. 2000;139:437-45

Stefanick ML (see Bittner et al). 2000;139:288-96 Stevenson LW (see Granger et al). 2000;139:609-17

Steyerberg EW, Bossuyt PMM, Lee KL. Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? 2000;139:745-51

Stinnett S (see Cohen et al). 2000:139:962-70

Stoddard MF (see Murray et al). 2000;139:e5 Stratos C (see Stefanadis et al). 2000;139:437-45

Strauer BE (see Heidland et al). 2000;139:1039-45

Sugahara Y (see Kawano et al). 2000;139:654-60 Sugawa M (see Masuoka et al). 2000;139:305-10

Sugrue DD (see Mahan et al). 2000;139:311-9

Suresh DP (see Holt et al). 2000;139:537-42

Suwa M, Ito T, Kobashi A, Yagi H, Terasaki F, Hirota Y,

Kawamura K. Myocardial integrated ultrasonic backscatter in patients with dilated cardiomyopathy: prediction of response to β-blocker therapy. 2000;139:905-12

Suzaki M (see Tanabe et al). 2000;139:889-94 Svane B (see Al-Khalili et al). 2000;139:971-8

Swedberg K (see Granger et al). 2000;139:609-17

Szalai C (see Szombathy et al). 2000;139:101-5

Szombathy T, Jánoskúti L, Szalai C, Császár A, Miklósi M, Mészáros A, Kempler P, László Z, Fenyvesi T, Romics L. Angiotensin II type 1 receptor gene polymorphism and mitral valve prolaps syndrome. 2000;139:101-5

T

Tabata T (see Oki et al). 2000;139:497-502 Tait RC (see Singer et al). 2000;139:558-60 (Reply) Takagi I (see Kawano et al). 2000:139:654-60

Takahashi M (see Tanabe et al). 2000;139:889-94 Tallarico D (see Rizzo et al). 2000;139:529-36

Talley ID (see Ellis et al). 2000:139:1046-53

Talreja D, Gruver C, Sklenar J, Dent J, Kaul S. Efficient utilization of echocardiography for the assessment of left ventricular systolic function. 2000;139:394-8

Tamura Y (see Yasue et al), 2000:139:e4

Tanabe Y, Oshima M, Suzuki M, Takahasi M. Determinants of delayed improvement in exercise capacity after percutaneous transvenous mitral commissurotomy. 2000;139:889-94

Tanaka H (see Yasue et al). 2000:139:e4

Tanaka T (see Masuoka et al). 2000;139:305-10

Tanguy J-F (see Wilensky et al). 2000;139:1061-70 Tateishi H (see Ishihara et al). 2000:139:881-8

Tavazzi L (see Lucreziotti et al). 2000;139:1088-95

Taylor MA (see Barsness et al). 2000;139:824-9

Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombacytopenia, and retreatment. 2000;139:S38-S45

Temple R. Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials. 2000;139:S133-S135

Teo KK (see Armstrong et al). 2000;139:820-3

Teraski F (see Suwa et al). 2000;139:905-12 Thaulow E (see Jørgensen et al). 2000;139:482-90

The ENRICHD investigators. Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD): study design and methods. 2000:139:1-9

The MAGIC Steering Committee. Rationale and design of the Magnesium in Coronaries (MAGIC) study: A clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction. 2000;139:10-4

Thelsen K (see Regar et al). 2000;139:623-37

Theroux P (see Topol et al). 2000;139:927-33

Third JLC (see Bremner et al). 2000 139:164-73 Thomas I (see Konstam et al). 2000;139:1081-7

Thompson CA, Yarzebski J, Goldberg RJ, Lessard D, Gore JM, Dalen JE. Changes over time in the incidence and case-fatality rates of primary ventricular fibrillation complicating acute myocardial infarction: Perspectives from the Worcester Heart Attack Study. 2000;139:1014-21

Thompson CR (see Armstrong et al). 2000;139:820-3

Thomsen C (see Søndergaard et al). 2000;139:667-74

Tischler MD (see Battle et al). 2000;139:346-51

Todo K (see Kawano et al). 2000;139:654-60 Tommaso C (see Barsness et al). 2000;139:824-9

Tomon M (see Okura et al). 2000;139:716-22

Topol EJ, Easton D, Amarenco P, Califf R, Harrington R, Graffagnino C, Davis S, Diener HD, Ferguson J, Fitzgerald Desmond, Shualb A, Koudstall PJ, Theroux P, Van de Werf F, Willerson JT, Chan R, Samuels R, Ilson B, Granett J. Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial. 2000;139:927-33

Topol EJ (see Brener et al). 2000;139:476-81 Topol EJ (see Hasdal et al). 2000;139:858-66

Topol EJ (see Marso et al). 2000;139:939-44 Tornos P (see Evangelista et al). 2000;139:773-81

Toshima T (see Kawano et al). 2000;139:654-60 Toutouzas K (see Stefanadis et al). 2000;139:437-45

Toutouzas P (see Stefanadis et al). 2000;139:437-45

Towbin JA (see Grenier et al). 2000;139:S86-S95 Trevi GP (see Brscic et al). 2000;139:979-84

Trohman RG (see Fogel et al). 2000;139:690-5 Tsiamis E (see Stefanadis et al). 2000;139:437-45

Tsiatis AA. Estimating the distribution of quality-adjusted life with censored data. 2000;139:S177-S181

Udelson JE, DeAbate A, Berk M, Neuberg G, Packer M, Vijay

NK, Gorwitt J, Smith WB, Kukin ML, LeJemtel T, Levine TB, Konstam MA. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. 2000;139:503-10

Udelson JE (see Konstam et al). 2000;139:1081-7 Ueda K (see Ishihara et al). 2000;139:881-8 Unger T. Neurohormonal modulation in cardiovascular disease.

2000;139:S2-S8

### V

Vaccarino V (see Krumholz et al). 2000;139:72-7
Vagelos R (see Meyers et al). 2000;139:78-84
Vahed S (see Bremner et al). 2000;139:164-73
Vaitkus PT. Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. 2000;139:1000-8

Valli M (see Deharo et al). 2000;139:1022-9
Van de Werf F (see Topol et al). 2000;139:927-33
van Herwaarden RH (see Ciampricotti et al). 2000;139:e3
van Veldhuisen DJ (see deVries et al). 2000;139:185-94
Vanoli E(see Lucreziotti et al). 2000;139:1088-95
Vardi GM (see Chol et al). 2000;139:643-8
Vasan RS, Levy D, Larson MG, Benjamin EJ. Interpretation of echocardiographic measurements: a call for standardization. 2000;139:412-22

Vavuranakis M (see Stefanadis et al). 2000;139:437-45 Venkatesan J (see Burket et al). 2000;139:64-71 Venkatesan J (see Burkett et al). 2000;139:64-71 Vijay NK (see Udelson et al). 2000;139:503-10 Villaneuva FS (see Lindner et al). 2000;139:231-40 Villemot J-P (see Alla et al). 2000;139:895-04 Villemot JP (see Echemann et al). 2000;139:624-31 Virion JM (see Echemann et al). 2000;139:624-31 Vlachopoulos C (see Stefanadis et al). 2000;139:437-45 von Domburg RT (see Elhendy et al). 2000;139:224-300

### W

Wagayama H (see Masuoka et al). 2000;139:305-10 Wagner GS (see Pettersson et al). 2000;139:352-8 Wakatsuki T (see Oki et al). 2000;139:497-502 Wallace DC. Mitochondrial defects in cardiomyopathy and neuromuscular disease. 2000;139:S70-S85 Wallentin L. Efficacy of low-molecular-weight heparin in acute coronary syndromes. 2000;139:S29-S32 Walsh RA (see Holt et al). 2000;139:S37-S42 Walter H (see Kastrati et al). 2000;139:208-16 Wamala SP (see Al-Khalili et al). 2000;139:971-8 Wang C-H (see Goff Ir et al). 2000;139:875-80 Wang Y (see Krumholz et al). 2000;139:72-7 Wardell J (see Alam et al). 2000;139:710-5 Warren SG (see Pettersson et al). 2000;139:352-8 Weatherly BD (see Cohen et al). 2000;139:962-70 Webb JG (see Carere et al). 2000;139:52-8 Wehrens XHT, Doevendans PA, Ophuis TJO, Wellens HJJ. A comparison of electrocardiographic changes during reperfusion of acute myocardial infarction by thrombolysis or percutaneous transluminal coronary angioplasty. 2000;139: 430-6

Wei JY (see Kyrie et al). 2000;139:94-100 Wei K (see Lindner et al). 2000;139:231-40 Weiner B (see Ellis et al). 2000;139:1046-53 Weinfurt KP (see Sheifer et al). 2000;139:649-53 Weir MR, Moser M. Diuretics and β-blockers: is there a risk for dyslipidemia? 2000;139:174-84
Weisman HF (see Mascelli et al). 2000;139:696-703
Weiss AT (see Gilon et al). 2000;139:1996-1100
Weiss R (see Shusterman et al). 2000;139:126-33
Weissman NJ, Cohen MC, Hack TC, Gilliam LD, Cohen JL,
Kitzman DW. Infusion versus bolus contrast echocardiography: a multicenter, open-label, crossover trial. 2000;139:399-

Weissman NJ (see Sheifer et al). 2000;139:649-53 Weissman NJ (see Sheiris et al). 2000;139:59-63 Weissman NJ (see Wilensky et al). 2000;139:1061-70 Wellens HJJ (see Wehrens et al). 2000;139:430-6 Werner F (see Regar et al). 2000;139:623-37 Wesley DJ (see Kitzman et al). 2000;139:1077-80 Wetter S (see Fasol et al). 2000;139:549-54 Whang DD (see Kereiakes et al). 2000;139:553-S60 Whellan DJ (see Sloan et al). 2000;139:567-76 Widner B (see Ledochouski et al). 2000;139:925-6 Wildermann NM (see Barsness et al). 2000;139:824-9

Wilensky RL, Tanguay J-F, Ito S, Bartorelli AL, Moses J, Williams DO, Bailey SR, Martin J, Bucher TA, Gallant P, Greenberg A, Popma JJ, Weissman NJ, Mintz GS, Kaplan AV, Leon MB. Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia. 2000; 139:1061-70

Willan A (see O'Brien et al). 2000;139:423-8
Willerson J (see Holmes et al). 2000;139:23-31
Willerson JT (see Topol et al). 2000;139:927-33
Williams DO (see Wilensky et al). 2000;139:1061-70
Wilson M (see Carere et al). 2000;139:52-8
Wilson PWF (see D'Agostino et al). 2000;139:272-81
Winter SC, Buist NRM. Cardiomyopathy in childhood, mitochondrial dysfunction, and the role of L-carnitine. 2000;139: S63-S69
Wiltkowsky AK (see Marrouche et al). 2000;139:e6



Xiang M (see Mack et al). 2000;139:993-9 Xie F (see Cwajg et al). 2000;139:675-83



Yagi H (see Suwa et al). 2000;139:905-12
Yamada H (see Oki et al). 2000;139:497-502
Yamaguchi T (see Yasue et al). 2000;139:e4
Yamazaki H (see Kinoshita et al). 2000;139:723-8
Yao Q (see Pinski et al). 2000;139:804-13
Yarzebski J (see Thompson et al). 2000;139:1014-21
Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, Ishikawa K, Masuda Y, Yamagochi T, Motomlya T, Tamura Y.
Comparison of the effects of alternate-day aspirin 81 mg and daily aspirin 162 mg on in-hospital cardiovascular events after myocardial infarction: an open-label, controlled, randomized clinical trial. 2000;139:e4

Yasunaga H (see Kawano et al). 2000;139:654-60 Yoshida H (see Okura et al). 2000;139:716-22 Yoshida K (see Okura et al). 2000;139:716-22 Yoshikawa J (see Okura et al). 2000;139:716-22 Yoshikawa T (see Okura et al). 2000;139:609-17 Yumota A (see Ishihara et al). 2000;139:881-8 Yusuf S. Challenges in the conduct and interpretation of phase II (pilot) randomized trials. 2000;139:S136-S142 Yusuf S (see Granger et al). 2000;139:609-17

Z

Zacharski LR, Chow B, Lavori PW, Howes PA, Bell MR, DiTommaso MA, Carnegie NM, Bech F, Amidi M, Muluk S. The Iron (Fe) and Atherosclerosis Study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. 2000;139:337-45
Zado ES (see Marchlinski et al). 2000;139:1009-13
Zahger D (see Gilon et al). 2000;139:1096-1100
Zannad F (see Alla et al). 2000;139:895-904
Zannad F (see Echemann et al). 2000;139:624-31
Zeman J (see Lindart et al). 2000;139:3101-8
Zeppa M (see Kaplan et al). 2000;139:378-87
Zhang Y (see Djoussé et al). 2000;139:704-9
Zohman LR (see Ades et al). 2000;139:543-8

# Subject index\*

### A

#### Accelerated intermittent harmonic imaging

Detection of angiographically significant coronary artery disease with accelerated intermittent imaging after intravenous administration of ultrasound contrast material (Cwajg et al). 2000:139:675-83

### Acute coronary syndrome

- Age and outcome after acute coronary syndromes without persistent ST-segment elevation (Hasdai et al). 2000;139:859-66
- Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide (Hasdai et al). 2000:139:454-60
- Effect of leukocytosis at initial examination on prognosis in patients with primary unstable angina (Lloyd-Jones et al). 2000;139:867-73
- Efficacy of low-molecular-weight heparin in acute coronary syndromes (Wallentin). 2000;139:S29-S32
- Patient-specific dosing of Ilb/Illa antogonists during acute coronary syndromes: rationale and design of the PARAGON B study (Moliterno et al). 2000;139:563-6
- Platelet glycoprotein IIb/IIIa receptor blockers: an appropriate-use model for expediting care in acute coronary syndromes (Kereiakes et al). 2000;139:S53-S60
- Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy (Cohen et al). 2000;139:962-70
- Stents covered by autologous venous grafts: feasibility and immediate and long-term results (Stefanadis et al). 2000; 139:437-45
- Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? (O'Brien et al). 2000;139:423-9

### Acute myocardial infarction

- Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up (Brscic et al). 2000; 139:979-84
- Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: results from the Third National Health and Nutrition Examination Survey (Giles et al). 2000;139:446-53
- Beneficial effect of prodromal angina pectoris is lost in elderly patients with acute myocardial infarction (Ishihara et al). 2000:139:881-8
- Benefits of magnesium in acute myocardial infarction: timing is crucial (Gyamlani et al). 2000;139:e2
- Changes over time in the incidence and case-fatality rates of primary ventricular fibrillation complicating acute myocardial infarction: perspectives from the Worcester Heart Attack Study (Thompson et al). 2000;139:1014-21
- Characteristics and outcomes in patients with acute myocardial infarction with ST-segment depression on initial electrocardiogram (Mahon et al). 2000;139:311-9
- Clinical significance of variable of ventricular late potentials detected before discharge in patients after myocardial infarction (Kozer et al). 2000;139:134-41

\*January, part 1, pp. 1-184; part 2, pp. S1-S28; February, part 1, pp. 185-370; part 2, S29-S60; part 3, S61-S130; March, pp. 371-562; April, pp. 563-744, S131-S210; May, pp. 745-926; June, pp. 927-1113.

- Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? (Steyerberg et al). 2000;139:745-51
- Clinical trials in acute myocardial infarction: when should we adjust for baseline characteristics? (Bailey). 2000;139:761-3 (Editorial)
- Collaborative Angiographic Patency Trial of Recombinant Staphylokinase (CAPTORS) (Armstrong et al). 2000;139:820-3
- Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition (Califf). 2000:139:S33-S37
- A comparison of electrocardiographic changes during reperfusion of acute myocardial infarction by thrombolysis or percutaneous transluminal coronary angioplasty (Wehrens et al). 2000;139:431-6
- Comparison of the effects of alternate-day aspirin 81 mg and daily aspirin 162 mg on in-hospital cardiovascular events after myocardial infarction: an open-label, controlled, randomized clinical trial (Yasue et al). 2000;139:e4
- Effect of leukocytosis at initial examination on prognosis in patients with primary unstable angina (Lloyd-Jones et al). 2000;139:867-73
- Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers (Pfeffer). 2000;139:S23-S28
- Guidelines for the diagnosis and management of unstable angina and nonQ-wave myocardial infarction: proposed revisions (Antman et al). 2000;139:461-75
- Management of heart failure among very old persons living in long-term care: has the voice of trials spread? (Gambassi et al). 2000;139:85-93
- Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction (Sloan et al). 2000;139:567-77
- Monitoring trends in severity of acute myocardial infarction: challenges for the next millennium (Goldberg). 2000; 139:768-70 (Editorial)
- Neutrophilia and congestive heart failure after acute myocardial infarction (Kyne et al). 2000;139:94-100
- Nonrandomized comparison between stent deployment and percutaneous transluminal coronary angioplasty in acute myocardial infarction (Katz et al). 2000;139:44-51
- Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials (Brener et al). 2000;139:476-81
- Prehospital delay time in acute myocardial infarction: an exploratory study on relation to hospital outcomes and cost (Caldwell et al). 2000;139:788-96
- Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis (Kastrati et al). 2000;139:208-16
- Rationale and design of the Magnesium in Coronaries (MAGIC) study: a clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction (MAGIC Steering Committee). 2000;139: 10-4
- Reduction of congestive heart failure symptoms by very early fibrinolytic therapy in acute myocardial infarction: a long-term follow-up (Gilon et al). 2000;139:1096-1100
- Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE II, RESCUE II, and other contemporary clincal experiences (Ellis et al). 2000;139:1046-53
- Sex differences in coronary artery size assessed by intravascular ultrasound (Sheifer et al). 2000;139:649-53
- When is angina good? Preconditioning in acute myocardial infarction (Granger). 2000;139:771-2 (Editorial)

#### Acute transmural myocardial infarction

Neutrophils and altered myocardial function (Kilgore et al). 2000;139:32-4 (Editorial)

#### Age factor

A comparison of nicorandil with isosorbid mononitrate in

### Age factors-Cont'd

elderly patients with stable coronary heart disease: the SNAPE study (Ciampricotti et al). 2000;139:e3

#### Aged

- Aortic atheroma morphology and the risk of ischemic stroke in a multiethnic population (Di Tullio et al). 2000;139:329-36
- Beneficial effect of prodromal angina pectoris is lost in elderly patients with acute myocardial infarction (Ishihara et al). 2000:139:881-8
- Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy (Konstam et al). 2000;139: 1081-7
- Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: analysis of the Cooperative Cardiovascular Project (Berger et al). 2009;139:985-92
- Management of heart failure among very old persons living in long-term care: has the voice of trials spread? (Gambassi et al). 2000:139:85-93
- Predictors of readmission among elderly survivors of admission with heart failure (Krumholz et al). 2000;139:72-7
- Transpulmonary passage of Albunex as a marker of intracardiac hemodynamics and outcome in chronic congestive heart failure (Sherman et al). 2000;139:782-7

#### AHJ at the Meetings

Highlights from the American Heart Association 72nd Scientific Sessions: November 6 to 10, 1999 (McGuire et al). 2000:139:359-70

#### Alcohol

Alcohol consumption and plasminogen activator inhibitor type 1: the National Heart, Lung, and Blood Institute Family Heart Study (Djoussé et al). 2000;139:704-9

### Altered myocardial function

Neutrophils and altered myocardial function (Kilgore et al). 2000;139:32-4 (Editorial)

#### American Heart Association

Cardiology, for what it's worth (Kandzari et al). 2000;139:392-3 (Editorial)

### Angina

When is angina good? Preconditioning in acute myocardial infarction (Granger). 2000;139:771-2 (Editorial)

#### Anginal chest pain

A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of postprocedural chest pain and minor myocardial necrosis after elective coronary stenting (Kurz et al). 2000;139:35-43

#### Angiographic follow-up

Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis (Kastrati et al). 2000;139:208-16

#### Angiography

Three-dimensional helical computed tomographic angiography in neonates and infants with complex congenital heart disease (Kawano et al). 2000;139:654-60

#### Angioplasty procedures

Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge (Carere et al), 2000;139:52-8

#### Angiotensin

Cardiac protection: evolving role of angiotensin receptor blockers (Califf et al). 2000;139:S15-S22

#### Angiotensin II

Neurohormonal modulation in cardiovascular disease (Unger). 2000;139:S2-S8

#### Angiotensin II type 1

Angiotensin II type 1 receptor gene polymorphism and mitral valve prolapse syndrome (Szombathy et al). 2000; 139:101-5

### Angiotensin-converting enzyme (ACE) inhibitors

Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors (Granger et al). 2000;139:609-17

#### Antiarrhythmic drugs

- An FDA perspective on antiarrhythmic drugs in phase II trials (Lipicky). 2000;139:S197-S199
- Development of antiarrhythmic drugs (Fisher). 2000;139:S200-S201

### Antiarrhythmic therapy

Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias (Fogel et al). 2000;139:690-5

#### Antiarrhythmics Versus Implantable Defibrillators (AVID) Study

Determinants of outcome in patients with sustained ventricular tachyarrhythmias: the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study Registry (Pinski et al). 2000;139: 804-13

#### Antiatherosclerotic therapy

Statins: effective antiatherosclerotic therapy (Blumenthal). 2000;139:577-86

#### Aortic coarctation

- Early results and medium-term follow-up of stent implantation for mild residual or recurrent aortic coarctation (Marshall et al). 2000;139:1054-60
- Endovascular stent treatment of aortic coarctation (Sanders). 2000;139:936-8 (Editorial)

#### Aortic regurgitation

Strategy for optimal aortic regurgitation quantification by Doppler echocardiography: agreement among different methods (Evangelista et al). 2000;139:773-81

#### Aortic valve disease

Sensitivity and specificity of transesophageal echocardioraphy for determination of aortic valve morphology (Espinal et al). 2000;139:1071-6

#### Arrhythmia

High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: a prospective, randomized double-blind crossover trial (Marrouche et al). 2000;139:e6

#### Arrhythmia prevention

Magnesium supplementation in the prevention of arrhythmias in pediatric patients undergoing surgery for congenital heart defects (Dorman et al). 2000;139:522-8

### Arterial thromboembolic disorders

Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein Ilb/Ila antagonist abciximab (Mascelli et al). 2000;139:696-702

#### Atherosclerosis

- Design of the blockade of the Glycoprotein IIb/IIIa Receptor to avoid vascular occlusion (BRAVO) trial (Topol et al). 2000:139:927-33
- Serial quantitative coronary angiography and coronary events (Mack et al). 2000;139:993-9

#### Atherosclerosis Risk in Communities (ARIC) Study, The

Trends in severity of hospitalized myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) Study, 1987– 1994 (Goff et al). 2000;139:874-9

#### Aspirin

Comparison of the effects of alternate-day aspirin 81 mg and daily aspirin 162 mg on in-hospital cardiovascular events after myocardial infarction: an open-label, controlled, randomized clinical trial (Yasue et al). 2000; 130:e4

### Athletes; see also Exercise factors; Sports medicine

Aortic root dilation among young competitive athletes: echocardiographic screening of 1929 athletes between 15 and 34 years of age (Kinoshita et al). 2000;139:723-8

### Atrial fibrillation

- Appropriate outcome measures in trials evaluating treatment of atrial fibrillation (Connolly). 2000;139:752-60
- Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension (Ciaroni et al). 2000;139:814-9
- Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series (LaPointe et al). 2000:139:114-21
- High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: a prospective, randomized double-blind crossover trial (Marrouche et al). 2000;139:e6
- Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators (Nanthakumar et al). 2000;139:797-803
- Prevalence and characteristics of escape rhythms after radiofrequency ablation of the atrioventricular junction: results from the Registry for AV Junction Ablation and Pacing in Atrial Fibrillation (Curtis et al). 2000;139:122-5
- Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study (Murray et al). 2000;139:e5
- Atrial septal aneurysms
  - Low incidence of embolic strokes with atrial septal aneurysms: a prospective, long-term study (Burger et al). 2000;139:149-52
- Atrioventricular junction
  - Prevalence and characteristics of escape rhythms after radiofrequency ablation of the atrioventricular junction: results from the Registry for AV Junction Ablation and Pacing in Atrial Fibrillation (Curtis et al). 2000;139: 122-5

### R

### Balloon angioplasty

- Role of cutting balloon angioplasty before coronary stent implantation (Park et al). 2000;139:e1
- β<sub>2</sub>-Adrenergic receptor polymorphisms
  - β<sub>2</sub>-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals (Hoit et al). 2000;139:537-42
- **β-Blocker improvement** 
  - β-Blocker improvement in diastolic performance: the yin and yang of ventricular function changes (Eichhorn et al). 2000;139:584-6 (Editorial)
- **β-Blocker therapy** 
  - Myocardial integrated ultrasonic backscatter in patients with dilated cardiomyopathy: prediction of response to β-blocker therapy (Suwa et al). 2000;139:905-12
  - β-Blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol (Capomolia et al.). 2000;139:596-608
- B-Blockers
  - Diuretics and β-blockers: is there a risk for dyslipidemia? (Weir et al). 2000;139:174-84
  - A rationale for the use of  $\beta$ -blockers as standard treatment for heart failure (Metra et al). 2000;139:511-21
- Bicuspid aortic valve
  - Sensitivity and specificity of transesophageal echocardioraphy for determination of aortic valve morphology (Espinal et al). 2000;139:1071-6
- Bleeding
  - Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment (Tcheng). 2000;139:S38-S45

- Blood pressure
  - B<sub>2</sub>.Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals (Hoit et al). 2000;139-537-45.

#### Bradyarrhythmia

Relations among hypoxemia, sleep stage, and bradyarrhythmia during obstructive sleep apnea (Koehler et al). 2000; 139:142-8

#### Bypass surgery

- Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series. 2000;139: 114-21
- Effect of variability in the interpretation of coronary angiograms on the appropriateness of use of coronary revascularization procedures (Leape et al). 2000;139:106-13
- Multivessel coronary stenting versus bypass surgery in patients with multivessel coronary artery disease and normal left ventricular function: immediate and 2-year long-term follow-up (Kim et al). 2000;139:638-42
- Understanding racial differences in cardiovascular care and outcomes: issues for the new millennium (East et al). 2000;139:764-6 (Editorial)

## C

### Calcium channel blockers

- Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction (Udelson et al). 2000;139:503-10
- Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines (de Vries et al). 2000;139:185-94

### Cardiac arrhythmia

- Appropriate outcome measures in trials evaluating treatment of atrial fibrillation (Connolly). 2000;139:752-60
- Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series. 2000;139:114-21

#### Cardiac Arrhythmia Pilot Study (CAPS)

- Development of antiarrhythmic drugs (Fisher). 2000;139:S200-S201 Cardiac catheterization
  - Quantification of mitral regurgitation in the cardiac catheterization laboratory with contrast echocardiography (Buckley et al). 2000:139:1109-13
  - Understanding racial differences in cardiovascular care and outcomes: issues for the new millennium (East et al). 2000;139:764-6 (Editorial)

#### Cardiac chest pain

Role of soluble and platelet-bound P-sectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department (Gurbel et al). 2000;139: 320-8

#### Cardiac cycles

β-Blocker improvement in diastolic performance: the yin and yang of ventricular function changes (Eichhorn et al). 2000;139:584-6 (Editorial)

#### Cardiac defibrillators

Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators (Nanthakumar et al). 2000;139:797-803

### Cardiac Insufficiency Bisoprolol Study (CIBIS)

Predictors of medical events in patients enrolled in the Cardiac Insufficiency Bisoprolo Study (CIBIS): a study of the interactions between β-blocker therapy and occurrence of critical events using analysis of competitive risks (Funck-Brentano et al.). 2000;139:262-71

### Cardiac procedures

Severity of coronary artery disease in black and white male veterans and likelihood of revascularization (Peniston et al). 2000:139:840-7

#### Cardiac protection

Cardiac protection: evolving role of angiotensin receptor blockers (Califf et al). 2000;139:S15-S22

Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers (Pfeffer). 2000;139:S23-S28

#### Cardiac structural changes

New insights in cardiac structural changes in patients with Fabry's disease (Linhart et al). 2000;139:1101-8

#### Cardiology

Appropriate outcome measures in trials evaluating treatment of atrial fibrillation (Connolly). 2000;139:752-60

Cardiology, for what it's worth (Kandzari et al). 2000;139:392-3 (Editorial)

Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? (Steyerberg et al). 2000;139: 745-51

Prevalence of nonfatal coronary heart disease among American adults (Ford et al). 2000;139:371-7

Three-dimensional echocardiographic assessment of annular shape changes in the normal and regurgitant mitral valve (Kaplan et al). 2000;139:378-87

When not doing tests is the right thing to do (Gibbons). 2000; 139:388-9 (Editorial)

### Cardiomyopathy; see also Dilated cardiomyopathy

Introduction (Feldman). 2000;139:S61-S62

Design and implementation of the North American Pediatric Cardiomyopathy Registry (Grenier et al). 2000;139:S86-S95

Mitochondrial defects in cardiomyopathy and neuromuscular disease (Wallace). 2000;139:S70-S87

#### Cardiovascular conditions

Rationale and design of the OPTIME CHF trial: outcomes of a Prospective Trial of Intravenous Milrionone for Exacerbations of Chronic Heart Failure (Cuffe et al). 2000;139:15-22

#### Cardiovascular disease

Introduction (Califf et al). 2000;139:S131-S132

Changes in lipoprotein(a) concentration after orthotopic heart transplantation (DeNofrio et al). 2000;139:729-33

Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials (Temple). 2000; 139:S133-S135

Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods (ENRICHD investigators), 2000;139:1-9

Neurohormonal modulation in cardiovascular disease (Unger). 2000;139:S2-S8

#### Cardiovascular disorders

Pericardial and pleural effusions in decompensated chronic heart failure (Kataoka). 2000;139:918-23

#### Cardiovascular medicine

Acute ischemic heart disease (Granger et al). 2000;139:S189-S192 Chronic ischemic heart disease (Gent et al). 2000;139:S182-S188

Introduction (Califf et al). 2000;139:S131-S210

Design and interpretation of equivalence trials (Fleming). 2000;139:S171-S176

Development of antiarrhythmic drugs (Fisher). 2000;139:S200-S201 Economic end points in phase II trials (Mark et al). 2000; 139:S155-S157

Equivalence and noninferiority trials (Siegel). 2000;139:S166-S170 Estimating the distribution of quality-adjusted life with censored data (Tsiatis). 2000;139:S177-S181

How should phase II trials in cardiovascular medicine be conducted? (Califf et al). 2000;139:S131-S132 Role of clinical nonfatal end points in cardiovacular Phase II/III clinical trials, The (O'Connor et al). 2000;139:S143-S154

Sample size and interim analysis issues for close selection (Lee). 2000;139:S161-S165

Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials (Parker et al). 2000;139: 952-61

Surrogate end points in cardiovascular disease trials (Fleming). 2000;139:S193-S196

#### Carnitine

Regulation of carbohydrate metabolism in ischemia and reperfusion (Lopaschuk). 2000;139:S115-S119

#### Carnitine transporter defect

Familial carnitine transporter defect: a treatable cause of cardiomyopathy in children. (Pierpont et al). 2000:139:896-8106

#### Carvedilol therapy

β-Blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol (Capomolla et al). 2000;139:596-608

#### Chemical cardioversion

High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: a prospective, randomized, double-blind crossover trial (Marrouche et al). 2000;139:e6

#### Chest pain; see also Anginal chest pain; Cardiac chest pain; Noncardiac chest pain

Angiotensin II type 1 receptor gene polymorphism and mitral valve prolapse syndrome (Szombathy et al). 2000:139:101-5

#### Child

Familial carnitine transporter defect: a treatable cause of cardiomyopathy in children. (Pierpont et al). 2000;139; \$96-\$106

Cardiomyopathy in childhood, mitochondrial dysfunction, and the role of L-carnitine (Winter et al). 2000;139:S63-S69

#### Cholesterol

Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels (Masuoka et al). 2000;139:305-10

Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events? (Cohen et al). 2000;139:734-8

#### Chronic asymptomatic aortic regurgitation

Vasodilatation with felodipine in chronic asymptomatic aortic regurgitation (Søndergaard et al). 2000;139:667-74

### Chronic heart failure

Five-minute recording of heart rate varibility in severe chronic heart failure: correlates with right ventricular function and prognostic implications (Lucreziotti et al). 2000;139:1088-95

Pericardial and pleural effusions in decompensated chronic heart failure (Kataoka). 2000;139:918-23

Predictors of medical events in patients enrolled in the Cardiac Insufficiency Bisoprolo Study (CIBIS): a study of the interactions between β-blocker therapy and occurrence of critical events using analysis of competitive risks (Funck-Brentano et al). 2000;139:262-71

Rationale and design of the OPTIME CHF trial: outcomes of a Prospective Trial of Intravenous Milrionone for Exacerbations of Chronic Heart Failure (Cuffe et al). 2000;139:15-22

Relation of changes over time in ventricular size and function to those in exercise capacity in patients with chronic heart failure (Florea et al). 2000;139:913-7

β-Blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol (Capomolla et al). 2000;139:596-608

Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration (Rizos), 2000;139:S120-S124

#### Chronic immune activation

Helicobacter pylori and chronic immune activation (Ledochouski et al) (Letter); (Arbustini and Morbini) (Reply). 2000;139:925-8

#### Chronic obstructive pulmonary disease

Safety assessment of perflenapent emulsion for echocardiographic contrast enhancement in patients with congestive heart failure or chronic obstructive pulmonary disease (Kitzman et al). 2000;139:1077-80

### Circadian patterns

Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men (Brenner et al). 2000;139:164–73 trials (Lipicky). 2000;139:S197-S199

# Clinical trials; see also Phase II clinical trials; Phase III clinical trials

- An FDA perspective on antiarrhythmic drugs in phase II Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment (Tcheng). 2000;139:S38-S45
- Clinical trials in acute myocardial infarction: when should we adjust for baseline characteristics? (Bailey). 2000;139:761-3 (Editorial)
- Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension (Ciaroni et al). 2000;139:814-9
- Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? (Steyerberg et al). 2000;139:745-51
- Comparison of the effects of alternate-day aspirin 81 mg and daily aspirin 162 mg on in-hospital cardiovascular events after myocardial infarction: an open-label, controlled, randomized clinical trial (Yasue et al). 2000;139:e4
- Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials (Temple). 2000; 139:S133-S135
- Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure (Packer). 2000; 139:S202-S206
- Design of phase II trials in congestive heart failure (DeMets), 2000;139:S207-S210
- Differential clinical prognotistic classifications in dilated and ischemic advanced heart failure: the EPICAL study (Alla et al). 2000;139:895-904
- Select-drop designs in clinical trials (Ellenberg). 2000;139: \$158-\$160
- Equivalence and noninferiority trials (Siegel). 2000;139:S166-

#### Congenital heart disease

- Determinants of delayed improvement in exercise capacity after percutaneous transvenous mitral commissurotomy (Tanabe et al). 2000:139:889-94
- Three-dimensional helical computed tomographic angiography in neonates and infants with complex congenital heart disease (Kawano et al). 2000;139:654-60

#### Congestive heart failure

- Differential clinical prognotistic classifications in dilated and ischemic advanced heart failure: the EPICAL study (Alla et al). 2000;139:895-904
- Management of heart failure among very old persons living in long-term care: has the voice of trials spread? (Gambassi et al). 2000;139:85-93
- Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan (Moe et al). 2000;139:587-95
- Neutrophilia and congestive heart failure after acute myocardial infarction (Kyne et al). 2000;139:94-100
- Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors (Granger et al). 2000;139:609-17

- Reduction of congestive heart failure symptoms by very early fibrinolytic therapy in acute myocardial infarction: a longterm follow-up (Gilon et al). 2000;139:1096-1100
- Transpulmonary passage of Albunex as a marker of intracardiac hemodynamics and outcome in chronic congestive heart failure (Sherman et al). 2000;139:782-87

### Contrast echocardiography

Quantification of mitral regurgitation in the cardiac catheterization laboratory with contrast echocardiography (Buckley et al). 2000;139:1109-13

#### Cooperative Cardiovascular Project

Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: analysis of the Cooperative Cardiovascular Project (Berger et al). 2000:139:985-92

#### Coronary angiograms

Effect of variability in the interpretation of coronary angiograms on the appropriateness of use of coronary revascularization procedures (Leape et al). 2000;139:106-13

#### Coronary angiographic measures

Serial quantitative coronary angiography and coronary events (Mack et al). 2000;139:993-9

### Coronary angioplasty

Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge (Carere et al). 2000;139:52-8

### Coronary arteries

Adjunctive intracoronary dipyridamole in the interventional treatment of small coronary arteries: a prospectively randomized trial (Heidland et al), 2000;139:1039-45

### Coronary artery disease

- Accuracy of dobutamine technetium 99m sestomibi SPECT imaging for the diagnosis of single-vessel coronary artery disease: comparison with echocardiography (Elhendy et al). 2000:139:224-30
- Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up (Brscic et al). 2000;139:979-84
- Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels (Masuoka et al). 2000;139:305-10
- Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events? (Cohen et al). 2000;139:734-8
- Clinical importance of risk factors and exercise testing for prediction of significant coronary artery stenosis in women recovering from unstable coronary artery disease: the Stockholm Female Coronary Risk Study (Al-Kahalili et al). 2000;139:971-8
- Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure (Vaitkus). 2000;139:1000-8
- Detection of angiographically significant coronary artery disease with accelerated intermittent imaging after intravenous administration of ultrasound contrast material (Cwaig et al). 2000;139:675-83
- Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions (Antman et al). 2000;139:461-75
- Increased expression of hemostasis markers in the coronary circulation in patients with coronary artery disease (Hojo et al) (Letter). 2000;139:5612
- Long-term estrogen replacement therapy is associated with improved exercise capacity in postmenopausal women without known coronary artery disease (Redberg et al). 2000:139:739-44
- Multivessel coronary stenting versus bypass surgery in

### Coronary artery disease-Cont'd

patients with multivessel coronary artery disease and normal left ventricular function: immediate and 2-year long-term follow-up (Kim et al). 2000;139:638-42

Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy (Cohen et al). 2000;139:962-70

Race and sex differences in the management of coronary artery disease (Sheifer et al). 2000;139:848-57

Severity of coronary artery disease in black and white male veterans and likelihood of revascularization (Peniston et al), 2000:139:840-7

Stents covered by autologous venous grafts: feasibility and immediate and long-term results (Stefanadis et al). 2000; 139:437-45

When not doing tests is the right thing to do (Gibbons). 2000;139:388-9 (Editorial)

#### Coronary heart disease

Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: results from the Third National Health and Nutrition Examination Survey (Giles et al). 2000;139:446-53

A comparison of nicorandil with isosorbid mononitrate in elderly patients with stable coronary heart disease: the SNAPE study (Ciampricotti et al). 2000;139:e3

A controlled trial of cardiac rehabilitation in the home setting using electrocardiographic and voice transtelphonic monitoring (Ades et al). 2000;139:543-48

Correlates of high HDL cholesterol among women with coronary heart disease (Bittner et al). 2000;139:288-97

Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods (ENRICHD investigators). 2000;139:1-9

Monitoring trends in severity of acute myocardial infarction: challenges for the next millennium (Goldberg). 2000; 139:768-70 (Editorial)

Prevalence of nonfatal coronary heart disease among American adults (Ford et al). 2000;139:371-7

Trends in severity of hospitalized myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1994 (Goff et al). 2000;139:874-80

#### Coronary interventional devices

Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network database (Peterson et al). 2000;139:198-207

#### Coronary revascularization

Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial (Lincoff). 2000:139:546-552

#### Coronary revascularization procedures

Effect of variability in the interpretation of coronary angiograms on the appropriateness of use of coronary revascularization procedures (Leape et al). 2000;139:106-13

### Coronary risk appraisal

Primary and subsequent coronary risk appraisal: new results from The Framingham Study (D'Angostino et al). 2000; 139:272-81

### Coronary vessels

Clinical and angiographic outcome after angiography-guided stent placement in small coronary vessels (Lau et al). 2000;139:830-9

#### Correction

Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty (Haase et al). (1999;137:234-40). 2000;139:1060

### Coumarin agent

Effect of pregnancy on the duration of bovine pericardial

bioprostheses (James) (Letter); (Salazar and Izaguirre) (Reply). 2000;139:924-5

### D

#### Death

Age and outcome after acute coronary syndromes without persistent ST-segment elevation (Hasdai et al). 2000;139:859-66

Aortic root dilation among young competitive athletes: echocardiographic screening of 1929 athletes between 15 and 34 years of age (Kinoshita et al). 2000;139:723-8

Changes over time in the incidence and case-fatality rates of primary ventricular fibrillation complicating acute myocardial infarction: perspectives from the Worcester Heart Attack Study (Thompson et al). 2000;139:1014-21

Clinical significance of variable of ventricular late potentials detected before discharge in patients after myocardial infarction (Kozer et al). 2000;139:134-41

Effects of mental stress on brachial artery flow-mediated vasodilation in healthy normal individuals (Harris et al). 2000:139:405-11

Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan (Moe et al). 2000;139:587-95

Prediction of death after percutaneous coronary interventional procedures (Rihal et al). 2000;139:1032-8

Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy (Cohen et al). 2000;139:962-70

Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting (Marso et al). 2000;139:939-44

#### Depression; see also Mental stress

Characteristics and outcomes in patients with acute myocardial infarction with ST-segment depression on initial electrocardiagram (Mahon et al). 2000;139:311-9

Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods (ENRICHD investigators). 2000;139:1-9

#### Diabetes mellitus

Influence of proteinuria on long-term outcome among patients with diabetes: the evidence continues to accumulate (McGuire). 2000;139:934-5 (Editorial)

Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial (Lincoff). 2000;139:546-552

Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting (Marso et al). 2000;139:939-44

Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries (Dwyer et al). 2000;139:297-304

### Diagnostic testing

Efficient utilization of echocardiography for the assessment of left ventricular systolic function (Talreja et al). 2000;139:394-8

#### Dihydropyridines

Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines (de Vries et al). 2000;139:185-94

#### Dilated cardiomyopathy

Familial carnitine transporter defect: a treatable cause of cardiomyopathy in children. (Pierpont et al). 2000;139:S96-S106

Myocardial integrated ultrasonic backscatter in patients with dilated cardiomyopathy: prediction of response to  $\beta$ -blocker therapy (Suwa et al). 2000;139:905-12

Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration (Rizos), 2000;139:S120-S124

#### **Diuretics**

Diuretics and β-blockers: is there a risk for dyslipidemia? (Weir et al). 2000;139:174–84

#### Drugs

An FDA perspective on antiarrhythmic drugs in phase II trials (Lipicky). 2000;139:S197-S199

#### Doppler methods

- Detection of left ventricular regional relaxations abnormalities and asynchrony in patients with hypertrophic cardiomyopathy with the use of tissue Doppler imaging (Oki et al). 2000;139:497-502
- Impact of Doppler-derived left ventricular diastolic performance on exercise capacity in normal individuals (Okura et al). 2000;139:716-22
- Mobile thrombi in the obdominal aorta in cases of lower extremity embolic arterial occlusion: value of extended transthoracic echocardiography (Spittell et al). 2000;139:241-4
- Power Doppler harmonic imaging: a feasibility study of a new technique for the assessment of myocardial perfusion (Senior et al). 2000;139:245-51
- Strategy for optimal aortic regurgitation quantification by Doppler echocardiography: agreement among different methods (Evangelista et al). 2000;139:773-81

#### Dyslipidemia

Diuretics and β-blockers: is there a risk for dyslipidemia? (Weir et al). 2000;139:174-84

### E

### **Echocardiographic evaluation**

- Continuous monitoring of an endocardial index of myocardial contractility during head-up tilt test (Deharo et al). 2000; 139:1022-9
- Efficient utilization of echocardiography for the assessment of left ventricular systolic function (Talreja et al). 2000;139:394-8 Interpretation of echocardiographic measurements: a call for
- standardization (Vasan et al). 2000;139:412-22 Left ventricular function, cardiac dysrhythmias, atrial activation,
- Left ventricular function, cardiac dysrhythmias, atrial activation and volumes in nondipper hypertensive individuals with left ventricular hypertrophy (Rizzo et al). 2000;139:529-36
- Three-dimensional echocardiographic assessment of annular shape changes in the normal and regurgitant mitral valve (Kaplan et al). 2000;139:378-87

#### Echocardiography; see also Contrast echocardiography; Transesophageal echocardiography; Transthoracic echocardiography

- Accuracy of dobutamine technetium 99m sestomibi SPECT imaging for the diagnosis of single-vessel coronary artery disease: comparison with echocardiography (Elhendy et al). 2000;139:224-30
- Early dobutamine echocardiography predicts improvement in regional and global left ventricular function after reperfused acute myocardial infarction without residual stenosis of the infarct-related artery (Bolognese et al). 2000;139:153-63
- Infusion versus bolus contrast echocardiography: a multicenter, open-label, crossover trial (Weissman et al). 2000;139:399-404
- Safety assessment of perflenapent emulsion for echocardiographic contrast enhancement in patients with congestive heart failure or chronic obstructive pulmonary disease (Kitzman et al). 2000;139:1077-80
- Strategy for optimal aortic regurgitation quantification by Doppler echocardiography: agreement among different methods (Evangelista et al). 2000;139:773-81

### **Echocardiography study**

Hemodynamic characteristics of congenital aortic stenosis: a quantitative stress echocardiography study (Battle et al). 2000;139:346-51

Spatial, individual, and temporal variation of the high-frequency QRS amplitudes in the 12 standard electrocardiagraphic leads (Pettersson et al). 2000;139:352-8

### Electrocardiographic changes

A comparison of electrocardiographic changes during reperfusion of acute myocardial infarction by thrombolysis or percutaneous transluminal coronary angioplasty (Wehrens et al.) 2000;139:431-6

### Electrocardiographic evaluation

- A controlled trial of cardiac rehabilitation in the home setting using electrocardiographic and voice transtelphonic monitoring (Ades et al), 2000;139:543-8
- Increase in ST-segment elevation immediately after reperfusion: cause and meaning (Greenfield). 2000;139:390-1 (Editorial)

#### Embolic strokes

Low incidence of embolic strokes with atrial septal aneurysms: a prospective, long-term study (Burger et al). 2000;139:149-52

#### **Endocardial index**

Continuous monitoring of an endocardial index of myocardial contractility during head-up tilt test (Deharo et al). 2000; 139:1022-9

#### **Endothelial cell dysfunction**

Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension (Lopes et al). 2000;139:618-23

#### **EPICAL study**

Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study (Echemann et al). 2000:139:624-31

### Escape rhythms

Prevalence and characteristics of escape rhythms after radiofrequency ablation of the atrioventricular junction: results from the Registry for AV Junction Ablation and Pacing in Atrial Fibrillation (Curtis et al). 2000;139:122–5

### Estrogen replacement therapy

Long-term estrogen replacement therapy is associated with improved exercise capacity in postmenopausal women without known coronary artery disease (Redberg et al). 2000;139:739-44

### Exercise factors

- Clinical importance of risk factors and exercise testing for prediction of significant coronary artery stenosis in women recovering from unstable coronary artery disease: the Stockholm Female Coronary Risk Study (Al-Kahalili et al). 2000;139:971-8
- A controlled trial of cardiac rehabilitation in the home setting using electrocardiographic and voice transtelephonic monitoring (Ades et al), 2000;139:543-54
- Determinants of delayed improvement in exercise capacity after percutaneous transvenous mitral commissurotomy (Tanabe et al). 2000;139:889-94
- Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction (Udelson et al). 2000;139:503-10
- Effects of exercise on QT dispersion in ischemic heart disease (Romano) (Letter); (Meijs et al) (Reply). 2000;139:556-8
- Hemodynamic characteristics of congenital aortic stenosis: a quantitative stress echocardiography study (Battle et al). 2000:139:346-51
- Impact of Doppler-derived left ventricular diastolic performance on exercise capacity in normal individuals (Okura et al). 2000;139:716-22
- Long-term estrogen replacement therapy is associated with improved exercise capacity in postmenopausal women without known coronary artery disease (Redberg et al). 2000;139:739-44
- Physiologic response to gain and loss in coronary minimal

### Exercise factors-cont'd

luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity (Jørgensen et al). 2000;139:482-90

Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials (Brener et al). 2000;139:476-81

Relation of changes over time in ventricular size and function to those in exercise capacity in patients with chronic heart failure (Florea et al). 2000;139:913-7

Signal-averaged P-wave abnormalities and atrial size in patients with and without idiopathic paroxysmal atrial fibrillation (Ishimoto et al). 2000;139:684-9

#### **Exercise testing**

Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited (Myers et al). 2000;139:78-84

#### Exercise training

Exercise training and myocardial remodeling in patients with reduced ventricular function: One-year follow-up with magnetic resonance imaging (Myers et al). 2000;139:252-61

#### Fabry's disease

New insights in cardiac structural changes in patients with Fabry's disease (Linhart et al). 2000;139:1101-8

### Fibrinolytic therapy

Collaborative Angiographic Patency Trial of Recombinant Staphylokinase (CAPTORS) (Armstrong et al). 2000;139:820-3

Combination therapy for acute myocardial infarction: Fibrinolytic therapy and glycoprotein IIb/IIIa inhibition (Califf). 2000;139:S33-S37

Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials (Brener et al). 2000;139:476-81

Reduction of congestive heart failure symptoms by very early fibrinolytic therapy in acute myocardial infarction: a longterm follow-up (Gilon et al). 2000;139:1096-1100

Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: Insights from the RESCUE II, RESCUE II, and other contemporary clincal experiences (Ellis et al). 2000;139:1046-53

#### Flosequinan

Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinan (Moe et al). 2000:139:587-95

#### Forearm blood flow

Peripheral resistance vessel dysfunction in Marfan syndrome (Nakamura et al). 2000;139:661-6

### Framingham Study, The

Primary and subsequent coronary risk appraisal: New results from The Framingham Study (D'Angostino et al). 2000; 139:272-81

#### Functional mitral regurgitant

Three-dimensional echocardiographic assessment of annular shape changes in the normal and regurgitant mitral valve (Kaplan et al). 2000:139:378-87

#### Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) III trial

Design and interpretation of equivalence trials (Fleming). 2000:139:S171-S176

### н

### Heart disease

Acute ischemic heart disease (Granger et al). 2000;139:S189-\$192

Cardiology, for what it's worth (Kandzari et al). 2000;139:392-3 (Editorial)

Chronic ischemic heart disease (Gent et al). 2000;139:S182-S188 Determinants of outcome in patients with sustained ventricular tachyarrhythmias: the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study Registry (Pinski et al), 2000:139:804-13

Highlights from the American Heart Association 72nd Scientific Sessions: November 6 to 10, 1999 (McGuire et al). 2000;139:359-70

Cardiomyopathy in childhood, mitochondrial dysfunction. and the role of L-carnitine (Winter et al). 2000;139:S63-

Spatial, individual, and temporal variation of the high-frequency QRS amplitudes in the 12 standard electrocardiagraphic leads (Pettersson et al). 2000;139:352-8

Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited (Myers et al). 2000;

Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study (Echemann et al). 2000:139:624-31

Differences between patients with heart failure treated by cardiologists, internists, family physicians, and other physicians: analysis of a large, statewide database (Philbin et al). 2000;139:491-6

Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction (Udelson et al). 2000;139:503-10

Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy (Konstam et al). 2000:139:1081-7

Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines (de Vries et al). 2000;139:185-94 Introduction. 2000:139:S1

Predictors of readmission among elderly survivors of admission with heart failure (Krumholz et al). 2000;139:72-7

#### Heart failure management

Management of heart failure among very old persons living in long-term care: has the voice of trials spread? (Gambassi et al). 2000;139:85-93

#### Heart failure treatment

A rationale for the use of β-blockers as standard treatment for heart failure (Metra et al). 2000;139:511-21

### Heart rate, increased

Dynamics of low-frequency R-R interval oscillations preceeding spontaneous ventricular tachycardia (Shusterman et al). 2000;139:126-34

### Heart rate variability

Five-minute recording of heart rate varibility in severe chronic heart failure: correlates with right ventricular function and prognostic implications (Lucreziotti et al). 2000:139:1088-95

#### **Heart surgery**

Magnesium supplementation in the prevention of arrhythmias in pediatric patients undergoing surgery for congenital heart defects (Dorman et al). 2000;139:522-8

#### Heart transplantation

Changes in lipoprotein(a) concentration after orthotopic heart transplantation (DeNofrio et al). 2000;139:729-33

#### Heparin

- Efficacy of low-molecular-weight heparin in acute coronary syndromes (Wallentin). 2000;139:S29-S32
- Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia (Wilensky et al). 2000:139:1061-70
- Low-molecular-weight heparin as optimal solution to therapeutic heparinization (Singer et al) (Letter); (Becker) (Reply). 2000;139:558-60
- Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIIb/IIa antagonist abciximab (Mascelli et al). 2000;139:696-702
- Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study (Murray et al), 2000;139:e5
- Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? (O'Brien et al). 2000;139:423-9

### Heparin Infusion Prior to Stenting (HIPS)

Heparin Infusion Prior to Stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia (Wilensky et al). 2000;139:1061-70

#### Homocyst(e)ine concentrations

Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination Survey (Giles et al). 2000;139:446-53

### Hormone systems

Neurohormonal modulation in cardiovascular disease (Unger). 2000;139:S2-S8

#### Hospitalization

- Changes over time in the incidence and case-fatality rates of primary ventricular fibrillation complicating acute myocardial infarction: perspectives from the Worcester Heart Attack Study (Thompson et al). 2000;139:1014-21
- Neutrophilia and congestive heart failure after acute myocardial infarction (Kyne et al). 2000;139:94-100
- Patient-specific dosing of IIb/IIIa antogonists during acute coronary syndromes: Rationale and design of the PARAGON B study (Moliterno et al). 2000;139:563-6
- Prehospital delay time in acute myocardial infarction: an exploratory study on relation to hospital outcomes and cost (Caldwell et al), 2000:139:788-96
- Transpulmonary passage of Albunex as a marker of intracardiac hemodynamics and outcome in chronic congestive heart failure (Sherman et al). 2000;139:782-87
- Trends in severity of hospitalized myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1994 (Goff et al). 2000;139:874-9

### Hypertension

- Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension (Ciaroni et al). 2000;139:814-9
- Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension (Lopes et al). 2000;139:618-23
- Left ventricular function, cardiac dysrhythmias, atrial activation, and volumes in nondipper hypertensive individuals with left ventricular hypertrophy (Rizzo et al). 2000;139: 520-36
- Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors (Granger et al). 2000;139:609-17
- Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a pre-

dominantly minority population with normal coronary arteries (Dwyer et al). 2000;139:297-304

#### Hypertrophic cardiomyopathy

Detection of left ventricular regional relaxations abnormalities and asynchrony in patients with hypertrophic cardiomyopathy with the use of tissue Doppler imagine (Oki et al). 2000;139:497-502

#### Hypoxemia

Relations among hypoxemia, sleep stage, and bradyarrhythmia during obstructive sleep apnea (Koehler et al). 2000; 139:142-8

### 1

#### Infective endocarditis

Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the Duke criteria (Roe et al). 2000; 139-945-51

#### Infusio

- Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series (LaPointe et al). 2000;138:114–21
- Infusion versus bolus contrast echocardiography: a multicenter, open-label, crossover trial (Weissman et al). 2000;139: 399-404

#### Inine

Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduced injury (Apstein). 2000; 130-5107-5114

### International Federation of Clinical Chemistry

Interpretation of echocardiographic measurements: a call for standardization (Vasan et al). 2000;139:412-22

#### Intra-aortic balloon counterpulsation

Sex and other predictors of intra-aortic balloon counterpulsation-related complications: prospective study of 1119 consecutive patients (Cohen et al). 2000;139:282-7

#### Intracoronary ultrasound

Role of intracoronary ultrasound after high-pressure stent implantation (Choi et al). 2000;139:643-8

### Intravascular ultrasound

- Natural history of intravascular ultrasound-detected edge dissections from coronary stent deployment (Sheris et al). 2000;139:59–63
- Sex differences in corollary artery size assessed by intravascular ultrasound (Sheifer et al). 2000;139:649-53

### Intravascular ultrasound imaging

Reproducibility of neointima quantification with motorized intravascular ultrasound pullback in stented coronary arteries (Regar et al). 2000;139:632-7

### Intravenous amiodarone

Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias (Fogel et al). 2000;139:690-5

#### Iron

The Iron (Fe) and Atherosclerosis Study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease (Zacharski et al). 2000;139:337-45

#### Ischemic stroke

Aortic atheroma morphology and the risk of ischemic stroke in a multiethnic population (Di Tullio et al). 2000;139: 329-36

### K

#### Kawasaki disease

Abnormal myocardial mechanics in Kawasaki disease: rapid response to γ-globulin (Moran et al). 2000;139:217-23

#### Kidney failure

Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure (Vaitkus). 2000;139:1000-8

#### L

#### L-Carnitine administration

Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration (Rizos), 2000;139:5120-5124

#### Left ventricular dilatation

Myocardial infarction and left ventricular remodeling: results of the CEDIM trial (Colonna et al). 2000;139:S124-S130

#### Left ventricular dysfunction

When not doing tests is the right thing to do (Gibbons). 2000;139:388-9 (Editorial)

#### Left ventricular function

Early dobutamine echocardiography predicts improvement in regional and global left ventricular function after reperfused acute myocardial infarction without residual stenosis of the infarct-related artery (Bolognese et al). 2000;139:153-63

Left ventricular function, cardiac dysrhythmias, atrial activation, and volumes in nondipper hypertensive individuals with left ventricular hypertrophy (Rizzo et al). 2000;139:529-36

### Left ventricular hypertrophy

New insights in cardiac structural changes in patients with Fabry's disease (Linhart et al). 2000;139:1101-8

Therapeutic options in minimizing left ventricular hypertrophy (Devereux). 2000;139:S9–S14

#### Left ventricular opacification

Infusion versus bolus contrast echocardiography: a multicenter, open-label, crossover trial (Weissman et al). 2000;139:399-404

#### Left ventricular systolic dysfunction

Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study (Echemann et al). 2000;139:624-31

### Left ventricular systolic function

Efficient utilization of echocardiography for the assessment of left ventricular systolic function (Talreja et al). 2000;139:394-8

#### Left ventricular systolic indexes

Impact of Doppler-derived left ventricular diastolic performance on exercise capacity in normal individuals (Okura et al). 2000;139:716-22

### Leukocytosis

Effect of leukocytosis at initial examination on prognosis in patients with primary unstable angina (Lloyd-Jones et al). 2000;139:867-73

#### Lipoprotein(a)

Changes in lipoprotein(a) concentration after orthotopic heart transplantation (DeNofrio et al). 2000;139:729-33

Lipoprotein(a) in atrial fibrillation (Lip) (Letter); (Igarashi and Aizawa) (Reply). 2000;139:555-6

Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men (Brenner et al). 2000;139:164-73

#### Low-density lipoprotein cholesterol

Statins: effective antiatherosclerotic therapy (Blumenthal). 2000;139:577-86

#### M

#### Magnesium

Magnesium supplementation in the prevention of arrhythmias in pediatric patients undergoing surgery for congenital heart defects (Dorman et al). 2000;139:522-8 Rationale and design of the Magnesium in Coronaries (MAGIC) study: a clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction (MAGIC Steering Committee). 2000;139:10-4

#### Magnesium deficiency

Benefits of magnesium in acute myocardial infarction: timing is crucial (Gyamlani et al). 2000;139:e2

#### Managed care

Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction (Sloan et al). 2000;139:567-77

#### Marfan syndrome

Peripheral resistance vessel dysfunction in Marfan syndrome (Nakamura et al). 2000;139:661-6

#### Medicaid

Medicaid, managed care, and the care of patients hospitalized for acute myocardial infarction (Sloan et al). 2000;139:567-77

### Medical therapy

Chronic ischemic heart disease (Gent et al). 2000;139:S182-S188

Mitral repair in patients with a ruptured papillary muscle (Fasol et al). 2000;139:554-9

#### Mental stress

Effects of mental stress on brachial artery flow-mediated vasodilation in healthy normal individuals (Harris et al). 2000:139:405-11

#### Metabolic therapies

Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduced injury (Apstein). 2000;139:S107-S114

#### Minor myocardial necrosis

A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of post-procedural chest pain and minor myocardial necrosis after elective coronary stenting (Kurz et al). 2000;139: 35-43

#### Mitral regurgitation

Quantification of mitral regurgitation in the cardiac catheterization laboratory with contrast echocardiography (Buckley et al). 2000;139:1109-13

#### Mitral valve prolapse syndrome

Angiotensin II type 1 receptor gene polymorphism and mitral valve prolapse syndrome (Szombathy et al). 2000;139:101-5

### Mitral valve regurgitation

Mitral repair in patients with a ruptured papillary muscle (Fasol et al). 2000;139:549-55

### Morbidity

Differences between patients with heart failure treated by cardiologists, internists, family physicians, and other physicians: analysis of a large, statewide database (Philbin et al). 2000;139:491-6

#### Mortality

Trends in severity of hospitalized myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1994 (Goff et al). 2000;139:874-80

#### Mortality rate

Rationale and design of the Magnesium in Coronaries (MAGIC) study: a clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction (MAGIC Steering Committee). 2000;139:10-4

#### Myocardial contrast echocardiography

Assessment of resting perfusion with myocardial contrast echocardiography: theoretical and practical considerations (Lindner et al). 2000;139:231-40

#### Myocardial infarction

Myocardial infarction and left ventricular remodeling: results of the CEDIM trial (Colonna et al). 2000;139:S124-S130

Right ventricular function in patients with first inferior myocardial infarction: assessment by tricuspid annular motion and tricuspid annular velocity (Alam et al). 2000;139:710-5

### Myocardial integrated backscatter

Myocardial integrated ultrasonic backscatter in patients with dilated cardiomyopathy: prediction of response to β-blocker therapy (Suwa et al). 2000;139:905-12

#### **Myocardial** mechanics

Abnormal myocardial mechanics in Kawasaki disease: rapid response to γ-globulin (Moran et al). 2000;139:217-23

Role of cutting balloon angioplasty before coronary stent implantation (Park et al). 2000;139:e1

#### Myocardial perfusion

Accuracy of dobutamine technetium 99m sestomibi SPECT imaging for the diagnosis of single-vessel coronary artery disease: comparison with echocardiography (Elhendy et al). 2000;139:224-30

Power Doppler harmonic imaging: a feasibility study of a new technique for the assessment of myocardial perfusion (Senior et al), 2000;139:245-51

#### Myocardial perfusion imaging

Detection of angiographically significant coronary artery disease with accelerated intermittent imaging after intravenous administration of ultrasound contrast material (Cwajg et al). 2000;139:675-83

### Myocardial remodeling

Exercise training and myocardial remodeling in patients with reduced ventricular function: one-year follow-up with magnetic resonance imaging (Myers et al). 2000;139: 252-61

#### Myocarditis

Abnormal myocardial mechanics in Kawasaki disease: rapid response to γ-globulin (Moran et al). 2000;139:217-23

Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis (Kastrati et al). 2000;139:208-16

#### Ν

#### National Cardiovascular Network database

Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network database (Peterson et al). 2000;139:198-207

## National Cholesteral Education Program, The

Correlates of high HDL cholesterol among women with coronary heart disease (Bittner et al). 2000;139:288-96

# National Heart, Lung, and Blood Institute Family Heart

Alcohol consumption and plasminogen activator inhibitor type 1: the National Heart, Lung, and Blood Institute Family Heart Study (Djoussé et al). 2000;139:704-9

#### Neuromuscular disease

Mitochondrial defects in cardiomyopathy and neuromuscular disease (Wallace). 2000;139:S70-S87

### Neutrophilia

Neutrophilia and congestive heart failure after acute myocardial infarction (Kyne et al). 2000;139:94-100

#### Nicorandi

A comparison of nicorandil with isosorbid mononitrate in elderly patients with stable coronary heart disease: the SNAPE study (Ciampricotti et al). 2000;139:e3

#### Noncardiac chest pain

Role of soluble and platelet-bound P-sectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department (Gurbel et al). 2000;139:320-8

## North American Pediatric Cardiomyopathy Registry

Design and implementation of the North American Pediatric Cardiomyopathy Registry (Grenier et al). 2000:139:S86-S95

#### Nytroglycerin

A double-blind, randomized study of the effect of immedi-

ate intravenous nitroglycerin on the incidence of postprocedural chest pain and minor myocardial necrosis after elective coronary stenting (Kurz et al). 2000;139: 35-43

### 0

#### Optime CHF

Rationale and design of the OPTIME CHF trial: Outcomes of a Prospective Trial of Intravenous Milrionone for Exacerbations of Chronic Heart Failure (Cuffe et al). 2000;139:15-22

### P

#### Papillary muscle

Mitral repair in patients with a ruptured papillary muscle (Fasol et al). 2000;139:549-54

#### **PARAGON B study**

Patient-specific dosing of IIb/IIIa antogonists during acute coronary syndromes: rationale and design of the PARAGON B study (Moliterno et al). 2000;139:563-6

#### Patient management

Differential clinical prognotistic classifications in dilated and ischemic advanced heart failure: the EPICAL study (Alla et al). 2000;139:895-904

### Percutaneous coronary artery intervention

Percutaneous coronary artery intervention: the last five years and the next five years (Feit). 2000;139:195-7 (Editorial)

#### Percutaneous coronary interventional procedures

Prediction of death after percutaneous coronary interventional procedures (Rihal et al). 2000;139:1032-8

### Percutaneous transluminal coronary angioplasty

Adjunctive intracoronary dipyridamole in the interventional treatment of small coronary arteries: a prospectively randomized trial (Heidland et al). 2000;139:1039-45

Clinical and angiographic outcome after angiography-guided stent placement in small coronary vessels (Lau et al). 2000;139:830-9

A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of postprocedural chest pain and minor myocardial necrosis after elective coronary stenting (Kurz et al). 2000;139:35-43

Effect of variability in the interpretation of coronary angiograms on the appropriateness of use of coronary revascularization procedures (Leape et al). 2000;139:106-13

Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia (Wilensky et al). 2000;139:1061-70

Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity (Jørgensen et al). 2000;139:482-90

Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts (Barsness et al). 2000;139:824-9

### Percutaneous transluminal coronary revascularization

The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: a double-blind placebo-controlled trial (Holmes et al). 2000;139:23-31

### Perflenapent emulsion

Safety assessment of perflenapent emulsion for echocardiographic contrast enhancement in patients with congestive heart failure or chronic obstructive pulmonary disease (Kitzman et al). 2000;139:1077-80

#### Perfusion

Assessment of resting perfusion with myocardial contrast echocardiography: theoretical and practical considerations (Lindner et al). 2000;139:231-40

#### Pericardial fluid

Pericardial and pleural effusions in decompensated chronic heart failure (Kataoka). 2000;139:924-5 (Reply)

#### Phase II clinical trials

Introduction (Califf et al). 2000;139 S131-S210

Challenges in the conduct and interpretation of phase II (pilot) randomized trials (Yusuf). 2000;139:S136-S142

Economic end points in phase II trials (Mark et al). 2000; 139:S155-S157

Role of clinical nonfatal end points in cardiovacular phase II/III clinical trials, The (O'Connor et al). 2000;139: \$143-\$154

Sample size and interim analysis issues for close selection (Lee). 2000;139:S161-S165

How should phase ii trials in cardiovascular medicine be conducted? (Califf et al). 2000;139:S131-S132

#### Phase III clinical trials

Challenges in the conduct and interpretation of phase II (pilot) randomized trials (Yusuf). 2000;139:S136-S142

Role of clinical nonfatal end points in cardiovacular phase II/III clinical trials, The (O'Connor et al). 2000;139: S143-S154

Sample size and interim analysis issues for close selection (Lee). 2000;139:S161-S165

Alcohol consumption and plasminogen activator inhibitor type 1: the National Heart, Lung, and Blood Institute Family Heart Study (Djoussé et al). 2000;139:704-9

Surrogate end points in cardiovascular disease trials (Fleming). 2000;139:S193-S196

#### Platelet activation

Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: Effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide (Hasdai et al). 2000;139: 454-60

#### Platelets

Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial (Topol et al). 2000;139:927-33

Platelet glycoprotein Ilb/Illa receptor blockers: an appropriate-use model for expediting care in acute coronary syndromes (Kereiakes et al). 2000;139:S53-S60

Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIa antagonist abciximab (Mascelli et al). 2000:139:696-702

### Pleural effusions

Pericardial and pleural effusions in decompensated chronic heart failure (Kataoka). 2000;139:918-23

#### Pregnancy

Effect of pregnancy on the duration of bovine pericardial bioprostheses (James) (Letter); (Salazar) (Reply). 2000;139:924-5

#### PRESTO

The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: a double-blind placebo-controlled trial (Holmes et al). 2000;139:23-31

### Prodromal angina pectoris

Beneficial effect of prodromal angina pectoris is lost in elderly patients with acute myocardial infarction (Ishihara et al). 2000;139:881-8

# Program on the Surgical Control of the Hypderlipidemias (POSCH) trial

Serial quantitative coronary angiography and coronary events (Mack et al). 200.0;139:993-9

#### Proteinuria

Influence of proteinuria on long-term outcome among

patients with diabetes: the evidence continues to accumulate (McGuire). 2000;139:934-5 (Editorial)

Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting (Marso et al). 2000;139:939-44

## Q

#### Quality-adjusted life

Estimating the distribution of quality-adjusted life with censored data (Tsiatis). 2000;139:S177-S181

#### Quantitative coronary angiography

Serial quantitative coronary angiography and coronary events (Mack et al). 2000;139:993-9

## R

#### Racial factors

Race and sex differences in the management of coronary artery disease (Sheifer et al). 2000;139:848-57

Severity of coronary artery disease in black and white male veterans and likelihood of revascularization (Peniston et al). 2000;139:840-7

Understanding racial differences in cardiovascular care and outcomes: issues for the new millennium. 2000;139:764-6 (Editorial)

#### Rapid eye movement

Relations among hypoxemia, sleep stage, and bradyarrhythmia during obstructive sleep apnea (Koehler et al). 2000;139:142-8

### Renal artery angioplasty

Renal artery angioplasty and stent placement: predictors of a favorable outcome (Burket et al). 2000;139:64-71

#### Renal artery stenosis

Renal artery angioplasty and stent placement: predictors of a favorable outcome (Burket et al). 2000;139:64-71

### Renin-angiotensin system

Introduction. 2000;139:S1

### Reperfusion

A comparison of electrocardiographic changes during reperfusion of acute myocardial infarction by thrombolysis or percutaneous transluminal coronary angioplasty (Wehrens et al). 2000;139:431-6

Increase in ST-segment elevation immediately after reperfusion: cause and meaning (Greenfield). 2000;139:390-1 (Editorial)

Prehospital delay time in acute myocardial infarction: an exploratory study on relation to hospital outcomes and cost (Caldwell et al). 2000;139;788-96

Regulation of carbohydrate metabolism in ischemia and reperfusion (Lopaschuk). 2000;139:S115-S119

### Reperfusion therapy

Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: analysis of the Cooperative Cardiovascular Project (Berger et al). 2000;139:985-92

#### Restenosi

The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: a double-blind placebo-controlled trial (Holmes et al). 2000;139:23-31

#### Restenosis

Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity (Jørgensen et al). 2000;139:482-90

#### Right ventricular function

Right ventricular function in patients with first inferior myocardial infarction: assessment by tricuspid annular motion and tricuspid annular velocity (Alam et al). 2000;139:710-5

#### Right ventricular outflow tract tachycardia

Sex-specific triggers for right ventricular outflow tract tachycardia (Marchlinski et al). 2000;139:1009-13

#### Risk factors

Clinical importance of risk factors and exercise testing for prediction of significant coronary artery stenosis in women recovering from unstable coronary artery disease: the Stockholm Female Coronary Risk Study (Al-Kahalili et al). 2000;139:971-8

### S

#### Saphenous vein graft treatment

Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts (Barsness et al). 2000;139:824-9

#### Sex factors

Race and sex differences in the management of coronary artery disease (Sheifer et al). 2000;139:848-57

Sex and other predictors of intra-aortic balloon counterpulsation-related complications: prospective study of 1119 consecutive patients (Cohen et al). 2000;139:282-7

Sex differences in coronary artery size assessed by intravascular ultrasound (Sheifer et al). 2000;139:649-53

Sex-specific triggers for right ventricular outflow tract tachycardia (Marchlinski et al). 2000;139:1009-13

#### Signal-averaged P-wave abnormalities

Signal-averaged P-wave abnormalities and atrial size in patients with and without idiopathic paroxysmal atrial fibrillation (Ishimoto et al). 2000;139:684-9

#### Smokin

Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide (Hasdai et al). 2000;139: 454-60

### Sports medicine

Aortic root dilation among young competitive athletes: Echocardiographic screening of 1929 athletes between 15 and 34 years of age (Kinoshita et al). 2000;139:723-8

#### Statins

Statins: effective antiatherosclerotic therapy (Blumenthal). 2000;139:577-86

### Stent deployment

Nonrandomized comparison between stent deployment and percutaneous transluminal coronary angioplasty in acute myocardial infarction (Katz et al). 2000;139:44-51

#### Stent implantation

Early results and medium-term follow-up of stent implantation for mild residual or recurrent aortic coarctation (Marshall et al). 2000;139:1054-60

Multivessel coronary stenting versus bypass surgery in patients with multivessel coronary artery disease and normal left ventricular function: immediate and 2-year long-term follow-up (Kim et al). 2000;139:638-42

Natural history of intravascular ultrasound-detected edge dissections from coronary stent deployment (Sheris et al). 2000:139:59-63

Percutaneous coronary artery intervention: the last five years and the next five years (Feit). 2000;139:195-7

Reproducibility of neointima quantification with motorized intravascular ultrasound pullback in stented coronary arteries (Regar et al). 2000;139:632-7

Role of cutting balloon angioplasty before coronary stent implantation (Park et al). 2000;139:e1

Role of intracoronary ultrasound after high-pressure stent implantation (Choi et al). 2000;139:643-8

#### Stent placement

Adjunctive intracoronary dipyridamole in the interventional treatment of small coronary arteries: a prospectively randomized trial (Heidland et al). 2000;139:1039-45

Clinical and angiographic outcome after angiography-guided stent placement in small coronary vessels (Lau et al). 2000;139:830-9

Primary intracoronary stenting in acute myocardial infarction: Long-term clinical and angiographic follow-up and risk factor analysis (Kastrati et al). 2000;139:208-16

Renal artery angioplasty and stent placement: predictors of a favorable outcome (Burket et al). 2000;139:64-71

#### Stent treatment

Endovascular stent treatment of aortic coarctation (Sanders). 2000:139:936-8 (Editorial)

#### Stents

Stents covered by autologous venous grafts: feasibility and immediate and long-term results (Stefanadis et al). 2000; 139:437-45

### Subgroup analyses

Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials (Parker et al). 2000;139: 952-61

#### Surgery; see Bypass surgery; Heart surgery

### T

#### Third National Health and Nutrition Examination Survey

Prevalence of nonfatal coronary heart disease among American adults (Ford et al). 2000;139:371-7

#### Thrombolysis in myocardial infacarction

Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE II, RESCUE II, and other contemporary clincal experiences (Ellis et al). 2000:139:1046-53

### Thrombosis

Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial (Topol et al). 2000;139:927-33

#### Tissue Doppler imaging; see Doppler methods Transesophageal echocardiography

Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the Duke criteria (Roe et al). 2000;139:945-51

Low incidence of embolic strokes with atrial septal aneurysms: a prospective, long-term study (Burger et al). 2000;139: 149-52

Mobile thrombi in the abdominal aorta in cases of lower extremity embolic arterial occlusion: value of extended transthorocic echocardiography (Spittell et al). 2000;139:241-4

Sensitivity and specificity of transesophageal echocardioraphy for determination of aortic valve morphology (Espinal et al). 2000;139:1071-6

Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study (Murray et al). 2000; 139:e5

### Transthoracic echocardiography

Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the Duke criteria (Roe et al). 2000;139:945-51

Mobile thrombi in the abdominal aorta in cases of lower extremity embolic arterial occlusion: Value of extended transthorocic echocardiography (Spittell et al). 2000;139:241-4

### U

# Ultrasound; see Intracoronary ultrasound; Intravascular ultrasound

#### Unstable angina

Age and outcome after acute coronary syndromes without persistent ST-segment elevation (Hasdai et al). 2000;139:858-66

Effect of leukocytosis at initial examination on prognosis in patients with primary unstable angina (Lloyd-Jones et al). 2000;139:867-73

Guidelines for the diagnosis and management of unstable anginaa and non-Q-wave myocardial infarction: proposed revisions (Antman et al). 2000;139:461-75

Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? (O'Brien et al). 2000;139:423-9



### Valvular heart disease

Determinants of delayed improvement in exercise capacity after percutaneous transvenous mitral commissurotomy (Tanabe et al). 2000;139:889-94

Three-dimensional echocardiographic assessment of annular shape changes in the normal and regurgitant mitral valve (Kaplan et al). 2000;139:378-87

#### Valvular insufficiency

Vasodilatation with felodipine in chronic asymptomatic aortic regurgitation (Sondergaard et al). 2000;139:667-74

#### Vasovagal syncope

Continuous monitoring of an endocardial index of myocardial contractility during head-up tilt test (Deharo et al). 2000; 139:1022-9

### Ventricular function changes

β-Blocker improvement in diastolic performance: the yin and yang of ventricular function changes (Eichhorn et al). 2000;139:574-6 (Editorial)

### Ventricular tachyarrhythmias

Clinical significance of variable of ventricular late potentials detected before discharge in patients after myocardial infarction (Kozer et al). 2000;139:134-41

Determinants of outcome in patients with sustained ventricular tachyarrhythmias: the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study Registry (Pinski et al), 2000;139:804-13

#### Ventricular tachycardia

Dynamics of low-frequency R-R interval oscillations preceeding spontaneous ventricular tachycardia (Shusterman et al). 2000;139:126–34

Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators (Nanthakumar et al). 2000;139:797-803

#### von Willebrand factor

Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension (Lopes et al). 2000;139:618-23



### Young adult

Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up (Brscic et al). 2000; 139:979-84

